Epithelial ovarian cancer: Evolution of management in t

Citation Report

#	Article	IF	Citations
1	Paeonol induces cytoprotective autophagy via blocking the Akt/mTOR pathway in ovarian cancer cells. Cell Death and Disease, 2019, 10, 609.	6.3	62
2	Etirinotecan pegol in women with recurrent platinum-resistant or refractory ovarian cancer. Expert Opinion on Investigational Drugs, 2019, 28, 667-673.	4.1	1
3	<p>Prognostic significance of FA score based on plasma fibrinogen and serum albumin in patients with epithelial ovarian cancer</p>. Cancer Management and Research, 2019, Volume 11, 7697-7705.	1.9	8
4	Application Of Adoptive Immunotherapy In Ovarian Cancer . OncoTargets and Therapy, 2019, Volume 12, 7975-7991.	2.0	4
5	<p>WTAP is a prognostic marker of high-grade serous ovarian cancer and regulates the progression of ovarian cancer cells</p>. OncoTargets and Therapy, 2019, Volume 12, 6191-6201.	2.0	63
6	Emerging serine-threonine kinase inhibitors for treating ovarian cancer. Expert Opinion on Emerging Drugs, 2019, 24, 239-253.	2.4	6
7	Targeting INHBA in Ovarian Cancer Cells Suppresses Cancer Xenograft Growth by Attenuating Stromal Fibroblast Activation. Disease Markers, 2019, 2019, 1-13.	1.3	20
8	<p>Efficacy And Safety Of Apatinib Treatment In Platinum-Resistant Recurrent Epithelial Ovarian Cancer: A Real World Study</p>. Drug Design, Development and Therapy, 2019, Volume 13, 3913-3918.	4.3	10
9	MiR-337â€"3p suppresses proliferation of epithelial ovarian cancer by targeting PIK3CA and PIK3CB. Cancer Letters, 2020, 469, 54-67.	7.2	45
10	Expression of Wnt pathway molecules is associated with disease outcome in metastatic high-grade serous carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 249-258.	2.8	8
11	Circular RNAs and their emerging roles as diagnostic and prognostic biomarkers in ovarian cancer. Cancer Letters, 2020, 473, 139-147.	7.2	54
12	Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts. Cancer Research, 2020, 80, 877-889.	0.9	15
13	A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer. Gynecologic Oncology, 2020, 156, 23-31.	1.4	40
14	Tanshinone I attenuates the malignant biological properties of ovarian cancer by inducing apoptosis and autophagy via the inactivation of PI3K/AKT/mTOR pathway. Cell Proliferation, 2020, 53, e12739.	5.3	175
15	Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. Journal of Hematology and Oncology, 2020, 13, 130.	17.0	166
16	<p>Changes of Intestinal Microbiota in Ovarian Cancer Patients Treated with Surgery and Chemotherapy</p>. Cancer Management and Research, 2020, Volume 12, 8125-8135.	1.9	22
17	Nanoparticles in precision medicine for ovarian cancer: From chemotherapy to immunotherapy. International Journal of Pharmaceutics, 2020, 591, 119986.	5.2	30
18	Integrative analysis of the common genetic characteristics in ovarian cancer stem cells sorted by multiple approaches. Journal of Ovarian Research, 2020, 13, 116.	3.0	5

#	Article	IF	Citations
19	Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS ONE, 2020, 15, e0237802.	2.5	223
20	LINC01133 contribute to epithelial ovarian cancer metastasis by regulating miR-495-3p/TPD52 axis. Biochemical and Biophysical Research Communications, 2020, 533, 1088-1094.	2.1	13
21	Rosmarinic Acid Methyl Ester Regulates Ovarian Cancer Cell Migration and Reverses Cisplatin Resistance by Inhibiting the Expression of Forkhead Box M1. Pharmaceuticals, 2020, 13, 302.	3.8	11
22	Investigating Patterns of Immune Interaction in Ovarian Cancer: Probing the O-glycoproteome by the Macrophage Galactose-Like C-Type Lectin (MGL). Cancers, 2020, 12, 2841.	3.7	10
23	TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells. BMC Cancer, 2020, 20, 960.	2.6	21
24	High-throughput approaches for precision medicine in high-grade serous ovarian cancer. Journal of Hematology and Oncology, 2020, 13, 134.	17.0	36
25	Incidence and mortality of ovarian cancer at the global, regional, and national levels, 1990â€"2017. Gynecologic Oncology, 2020, 159, 239-247.	1.4	35
26	Successful Treatment of Patients with Refractory High-Grade Serous Ovarian Cancer with<i>GOPC-ROS1</i>Fusion Using Crizotinib: A Case Report. Oncologist, 2020, 25, e1720-e1724.	3.7	8
27	CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Science Advances, 2020, 6, .	10.3	270
28	Modular Peptide Probe for Pre/Intra/Postoperative Therapeutic to Reduce Recurrence in Ovarian Cancer. ACS Nano, 2020, 14, 14698-14714.	14.6	46
29	Prognostic impact of tumor-infiltrating lymphocytes in high grade serous ovarian cancer: a systematic review and meta-analysis. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592096724.	3.2	36
30	Efficacy and safety updates of poly ADP-ribose polymerase (PARP) inhibitor maintenance in ovarian cancer from ASCO 2020. International Journal of Gynecological Cancer, 2020, 30, 1256-1257.	2.5	1
31	The Landscape and Therapeutic Implications of Molecular Profiles in Epithelial Ovarian Cancer. Journal of Clinical Medicine, 2020, 9, 2239.	2.4	24
32	Nearâ€infrared dyeâ€labeled antibody COC183B2 enables detection of tiny metastatic ovarian cancer and optimizes fluorescenceâ€guided surgery. Journal of Surgical Oncology, 2020, 122, 1207-1217.	1.7	4
33	Expression of palladin is associated with disease progression in metastatic highâ€grade serous carcinoma. Cytopathology, 2020, 31, 572-578.	0.7	2
34	Modeling the Diversity of Epithelial Ovarian Cancer through Ten Novel Well Characterized Cell Lines Covering Multiple Subtypes of the Disease. Cancers, 2020, 12, 2222.	3.7	10
35	Targeting Multiple Signaling Pathways in Cancer: The Rutin Therapeutic Approach. Cancers, 2020, 12, 2276.	3.7	105
36	<p>KCNH3 Predicts Poor Prognosis and Promotes Progression in Ovarian Cancer</p>. OncoTargets and Therapy, 2020, Volume 13, 10323-10333.	2.0	5

#	Article	IF	Citations
37	Morphological and molecular heterogeneity of epithelial ovarian cancer: Therapeutic implications. European Journal of Cancer, Supplement, 2020, 15, 1-15.	2.2	15
38	<p>The Natural Product Fucoidan Inhibits Proliferation and Induces Apoptosis of Human Ovarian Cancer Cells: Focus on the PI3K/Akt Signaling Pathway</p>. Cancer Management and Research, 2020, Volume 12, 6195-6207.	1.9	16
39	Role of ultrasound in the detection of recurrent ovarian cancer: a review of the literature. Gland Surgery, 2020, 9, 1092-1101.	1.1	14
40	Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy. Journal of Clinical Medicine, 2020, 9, 2967.	2.4	23
41	Controversies on the treatment of ovarian cancer with dose-dense chemotherapy. Chinese Clinical Oncology, 2020, 9, 53-53.	1.2	4
42	Impact of ERCC1, XPF and DNA Polymerase Î² Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts. Cancers, 2020, 12, 2398.	3.7	9
43	Implementing NGS-based<i>BRCA</i>tumour tissue testing in FFPE ovarian carcinoma specimens: hints from a real-life experience within the framework of expert recommendations. Journal of Clinical Pathology, 2021, 74, 596-603.	2.0	10
44	MIEF2 over-expression promotes tumor growth and metastasis through reprogramming of glucose metabolism in ovarian cancer. Journal of Experimental and Clinical Cancer Research, 2020, 39, 286.	8.6	26
45	CA125 and Ovarian Cancer: A Comprehensive Review. Cancers, 2020, 12, 3730.	3.7	174
46	<p>The Role of CCL20-CCR6 Axis in Ovarian Cancer Metastasis</p>. OncoTargets and Therapy, 2020, Volume 13, 12739-12750.	2.0	14
47	Polyphenols Extracted from Chinese Hickory (Carya cathayensis) Promote Apoptosis and Inhibit Proliferation through the p53-Dependent Intrinsic and HIF-1Î±-VEGF Pathways in Ovarian Cancer Cells. Applied Sciences (Switzerland), 2020, 10, 8615.	2.5	4
48	Expression of PAWR predicts prognosis of ovarian cancer. Cancer Cell International, 2020, 20, 598.	4.1	9
49	BMP signaling is a therapeutic target in ovarian cancer. Cell Death Discovery, 2020, 6, 139.	4.7	22
50	<p>Butorphanol Inhibits the Malignant Biological Behaviors of Ovarian Cancer Cells via Down-Regulating the Expression of TMEFF1</p>. OncoTargets and Therapy, 2020, Volume 13, 10973-10981.	2.0	7
51	Eukaryotic initiation factor 3B is overexpressed and correlates with larger tumor size, advanced FIGO stage, and shorter overall survival in epithelial ovarian cancer patients. Journal of Clinical Laboratory Analysis, 2020, 34, e23354.	2.1	2
52	Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib. Cell Death and Disease, 2020, 11, 380.	6.3	21
53	PLGA Nanoparticles for the Intraperitoneal Administration of CBD in the Treatment of Ovarian Cancer: In Vitro and In Ovo Assessment. Pharmaceutics, 2020, 12, 439.	4.5	53
54	Expressions and clinical significances of STAT3 and Grim19 in epithelial ovarian cancer. 3 Biotech, 2020, 10, 246.	2.2	2

#	Article	IF	Citations
55	CD24-targeted fluorescence imaging in patient-derived xenograft models of high-grade serous ovarian carcinoma. EBioMedicine, 2020, 56, 102782.	6.1	14
56	Expression of ACAP1 Is Associated with Tumor Immune Infiltration and Clinical Outcome of Ovarian Cancer. DNA and Cell Biology, 2020, 39, 1545-1557.	1.9	12
57	Expression of the cancer stem cell marker SSEA1 is associated with poor survival in metastatic high-grade serous carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 677-685.	2.8	1
58	The prognostic value of ITGA and ITGB superfamily members in patients with high grade serous ovarian cancer. Cancer Cell International, 2020, 20, 257.	4.1	25
59	Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1. Journal of Translational Medicine, 2020, 18, 220.	4.4	20
60	Targeting lipid droplet lysophosphatidylcholine for cisplatin chemotherapy. Journal of Cellular and Molecular Medicine, 2020, 24, 7187-7200.	3.6	12
61	Low junctional adhesion molecule-A expression is associated with an epithelial to mesenchymal transition and poorer outcomes in high-grade serous carcinoma of uterine adnexa. Modern Pathology, 2020, 33, 2361-2377.	5.5	4
62	Targeting Cancer Stem Cells to Overcome Therapy Resistance in Ovarian Cancer. Cells, 2020, 9, 1402.	4.1	46
63	Developing an Australian multi-module clinical quality registry for gynaecological cancers: a protocol paper. BMJ Open, 2020, 10, e034579.	1.9	5
64	Identification of PLK1 as a New Therapeutic Target in Mucinous Ovarian Carcinoma. Cancers, 2020, 12, 672.	3.7	20
65	Ovarian Cancer, Cancer Stem Cells and Current Treatment Strategies: A Potential Role of Magmas in the Current Treatment Methods. Cells, 2020, 9, 719.	4.1	43
66	MYC-regulated pseudogene HMGA1P6 promotes ovarian cancer malignancy via augmenting the oncogenic HMGA1/2. Cell Death and Disease, 2020, 11, 167.	6.3	29
67	Mitomycin C plus cisplatin for systemic treatment of recurrent BRCA1-associated ovarian cancer. Investigational New Drugs, 2020, 38, 1872-1878.	2.6	3
68	New Organometallic Ruthenium(II) Compounds Synergistically Show Cytotoxic, Antimetastatic and Antiangiogenic Activities for the Treatment of Metastatic Cancer. Chemistry - A European Journal, 2020, 26, 15170-15182.	3.3	49
69	CD24-targeted intraoperative fluorescence image-guided surgery leads to improved cytoreduction of ovarian cancer in a preclinical orthotopic surgical model. EBioMedicine, 2020, 56, 102783.	6.1	24
70	Death domain-associated protein (DAXX) expression is associated with poor survival in metastatic high-grade serous carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 857-864.	2.8	6
71	Cul4B promotes the progression of ovarian cancer by upregulating the expression of CDK2 and CyclinD1. Journal of Ovarian Research, 2020, 13, 76.	3.0	22
72	miR â€181a overexpression predicts the poor treatment response and earlyâ€progression of serous ovarian cancer patients. International Journal of Cancer, 2020, 147, 3560-3573.	5.1	7

#	ARTICLE	IF	CITATIONS
73	Efficacy and safety of low‑dose apatinib in ovarian cancer patients with platinum‑resistance or platinum‑refractoriness: A single‑center retrospective study. Cancer Medicine, 2020, 9, 5899-5907.	2.8	9
74	Proteome Profiling Uncovers an Autoimmune Response Signature That Reflects Ovarian Cancer Pathogenesis. Cancers, 2020, 12, 485.	3.7	9
75	Development of a near infrared protein nanoprobe targeting Thomsen-Friedenreich antigen for intraoperative detection of submillimeter nodules in an ovarian peritoneal carcinomatosis mouse model. Biomaterials, 2020, 241, 119908.	11.4	7
76	miR-6089/MYH9/β-catenin/c-Jun negative feedback loop inhibits ovarian cancer carcinogenesis and progression. Biomedicine and Pharmacotherapy, 2020, 125, 109865.	5.6	37
77	Niacin-ligated platinum(<scp>iv</scp>)–ruthenium(<scp>ii</scp>) chimeric complexes synergistically suppress tumor metastasis and growth with potentially reduced toxicity<i>in vivo</i>. Chemical Communications, 2020, 56, 3069-3072.	4.1	22
78	MASS SPECTROMETRY‑BASED MITOCHONDRIAL PROTEOMICS IN HUMAN OVARIAN CANCERS. Mass Spectrometry Reviews, 2020, 39, 471-498.	5.4	15
79	Dynamic analysis of N-glycomic and transcriptomic changes in the development of ovarian cancer cell line A2780 to its three cisplatin-resistant variants. Annals of Translational Medicine, 2020, 8, 289-289.	1.7	13
80	Neoadjuvant chemotherapy-related platinum resistance in ovarian cancer. Drug Discovery Today, 2020, 25, 1232-1238.	6.4	28
81	CD38 Predicts Favorable Prognosis by Enhancing Immune Infiltration and Antitumor Immunity in the Epithelial Ovarian Cancer Microenvironment. Frontiers in Genetics, 2020, 11, 369.	2.3	17
82	Synergistic enhancement of efficacy of platinum drugs with verteporfin in ovarian cancer cells. BMC Cancer, 2020, 20, 273.	2.6	9
83	Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience. Cells, 2020, 9, 903.	4.1	8
84	Targeting tumor microenvironment in ovarian cancer: Premise and promise. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1873, 188361.	7.4	105
85	Precision medicine and management of rheumatoid arthritis. Journal of Autoimmunity, 2020, 110, 102405.	6.5	56
86	The tubal epigenome – An emerging target for ovarian cancer. , 2020, 210, 107524.		10
87	Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. International Journal of Gynecological Cancer, 2020, 30, 903-915.	2.5	52
88	Oncogenic and drug-sensitive RET mutations in human epithelial ovarian cancer. Journal of Experimental and Clinical Cancer Research, 2020, 39, 53.	8.6	3
89	LGR4 overexpression is associated with clinical parameters and poor prognosis of serous ovarian cancer. Cancer Biomarkers, 2020, 28, 65-72.	1.7	8
90	Calcium Channels as Novel Therapeutic Targets for Ovarian Cancer Stem Cells. International Journal of Molecular Sciences, 2020, 21, 2327.	4.1	35

#	Article	IF	Citations
91	The negative feedback between miRâ€143 and DNMT3A regulates cisplatin resistance in ovarian cancer. Cell Biology International, 2021, 45, 227-237.	3.0	12
92	Diet and ovarian cancer risk: An umbrella review of systematic reviews and meta-analyses of cohort studies. Clinical Nutrition, 2021, 40, 1682-1690.	5.0	22
93	The phosphatase PTPN1/PTP1B is a candidate marker of better chemotherapy response in metastatic highâ€grade serous carcinoma. Cytopathology, 2021, 32, 161-168.	0.7	4
94	Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials. Critical Reviews in Oncology/Hematology, 2021, 157, 103145.	4.4	34
95	Noncoding RNA (ncRNA) Profile Association with Patient Outcome in Epithelial Ovarian Cancer Cases. Reproductive Sciences, 2021, 28, 757-765.	2.5	7
96	Stromal POSTN induced by TGF-Î²1 facilitates the migration and invasion of ovarian cancer. Gynecologic Oncology, 2021, 160, 530-538.	1.4	70
97	Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer. Gynecologic Oncology, 2021, 160, 32-39.	1.4	20
98	Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer. Cancer Gene Therapy, 2021, 28, 375-389.	4.6	8
99	Ameliorative effect of recombinant human lactoferrin on the premature ovarian failure in rats after cyclophosphamide treatments. Journal of Ovarian Research, 2021, 14, 17.	3.0	16
100	An Italian National Survey on Ovarian Cancer Treatment at first diagnosis. There's None so Deaf as those who will not Hear. Journal of Cancer, 2021, 12, 4443-4454.	2.5	5
101	Ferroptosis-Related Gene Model to Predict Overall Survival of Ovarian Carcinoma. Journal of Oncology, 2021, 2021, 1-14.	1.3	25
102	DNM3OS Facilitates Ovarian Cancer Progression by Regulating miR-193a-3p/MAP3K3 Axis. Yonsei Medical Journal, 2021, 62, 535.	2.2	5
103	PRSS1 Upregulation Predicts Platinum Resistance in Ovarian Cancer Patients. Frontiers in Cell and Developmental Biology, 2020, 8, 618341.	3.7	2
104	Combined Serum DKK3 and Circulating CD133 Cells as Prognostic Biomarkers for Ovarian Cancer Patients. OncoTargets and Therapy, 2021, Volume 14, 427-434.	2.0	7
105	Application of machine learning in prediction of Chemotherapy resistant of Ovarian Cancer based on Gut Microbiota. Journal of Cancer, 2021, 12, 2877-2885.	2.5	8
106	Sensitization of ovarian tumor to immune checkpoint blockade by boosting senescence-associated secretory phenotype. IScience, 2021, 24, 102016.	4.1	32
107	Coâ€Delivery of Paclitaxel and shMCLâ€1 by Folic Acidâ€Modified Nonviral Vector to Overcome Cancer Chemotherapy Resistance. Small Methods, 2021, 5, 2001132.	8.6	18
108	Comparisons of survival outcomes between bevacizumab and olaparib in <i>BRCA-</i> mutated, platinum-sensitive relapsed ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3052). Journal of Gynecologic Oncology, 2021, 32, e90.	2.2	2

#	Article	IF	Citations
109	<i>CREBBP</i> knockdown suppressed proliferation and promoted chemo-sensitivity via PERK-mediated unfolded protein response in ovarian cancer. Journal of Cancer, 2021, 12, 4595-4603.	2.5	7
110	Utility of adjuvant whole abdominal radiation therapy in ovarian clear cell cancer (OCCC): a pragmatic cohort study of women with classic immuno-phenotypic signature. Radiation Oncology, 2021, 16, 29.	2.7	5
111	Î±PD-1-mesoCAR-T cells partially inhibit the growth of advanced/refractory ovarian cancer in a patient along with daily apatinib. , 2021, 9, e001162.		20
112	MUC16 promotes EOC proliferation by regulating GLUT1 expression. Journal of Cellular and Molecular Medicine, 2021, 25, 3031-3040.	3.6	5
113	Emerging Roles for Ion Channels in Ovarian Cancer: Pathomechanisms and Pharmacological Treatment. Cancers, 2021, 13, 668.	3.7	16
114	Survival Analysis of Radiation Therapy in Ovarian Cancer: A SEER Database Analysis. Journal of Oncology, 2021, 2021, 1-11.	1.3	3
115	The Cancer-Testis Long Non-coding RNA PCAT6 Facilitates the Malignant Phenotype of Ovarian Cancer by Sponging miR-143-3p. Frontiers in Cell and Developmental Biology, 2021, 9, 593677.	3.7	6
116	Development and Validation of an Immune-Related Gene-Pair Model of High-Grade Serous Ovarian Cancer After Platinum-Based Chemotherapy. Frontiers in Oncology, 2020, 10, 626555.	2.8	0
117	Differential expression of PD-L1 between primary and metastatic epithelial ovarian cancer and its clinico-pathological correlation. Scientific Reports, 2021, 11, 3750.	3.3	22
118	Long Non-coding RNA LINC01969 Promotes Ovarian Cancer by Regulating the miR-144-5p/LARP1 Axis as a Competing Endogenous RNA. Frontiers in Cell and Developmental Biology, 2020, 8, 625730.	3.7	6
119	Comprehensive Analysis of Tumor Microenvironment Identified Prognostic Immune-Related Gene Signature in Ovarian Cancer. Frontiers in Genetics, 2021, 12, 616073.	2.3	15
121	CRISPR-cas9 genome editing delivery systems for targeted cancer therapy. Life Sciences, 2021, 267, 118969.	4.3	31
122	Monitoring the extracellular matrix remodeling of highâ€grade serous ovarian cancer with nonlinear optical microscopy. Journal of Biophotonics, 2021, 14, e202000498.	2.3	3
123	Development of Aptamer-Based Molecular Tools for Rapid Intraoperative Diagnosis and <i>In Vivo</i> Imaging of Serous Ovarian Cancer. ACS Applied Materials & Interfaces, 2021, 13, 16118-16126.	8.0	15
124	Identification of MEG8/miRâ€378d/SOBP axis as a novel regulatory network and associated with immune infiltrates in ovarian carcinoma by integrated bioinformatics analysis. Cancer Medicine, 2021, 10, 2924-2939.	2.8	9
125	Tumor Forkhead Box Q1 Is Elevated, Correlates with Increased Tumor Size, International Federation of Gynecology and Obstetrics Stage but Worse Overall Survival in Epithelial Ovarian Cancer Patients. Cancer Biotherapy and Radiopharmaceuticals, 2021, , .	1.0	1
126	Obesity and Energy Substrate Transporters in Ovarian Cancerâ€"Review. Molecules, 2021, 26, 1659.	3.8	6
127	Long-Term Follow-Up of a Female Patient Treated with Olaparibâ€"Hope for a Long Life without Relapse?. International Journal of Environmental Research and Public Health, 2021, 18, 3430.	2.6	1

#	ARTICLE	IF	CITATIONS
128	The Utility of Next-Generation Sequencing in Advanced Breast and Gynecologic Cancers. American Journal of Clinical Pathology, 2021, 156, 455-460.	0.7	3
129	VPS33B interacts with NESG1 to suppress cell growth and cisplatin chemoresistance in ovarian cancer. Cancer Science, 2021, 112, 1785-1797.	3.9	5
130	PGC1Î± Promotes Cisplatin Resistance in Ovarian Cancer by Regulating the HSP70/HK2/VDAC1 Signaling Pathway. International Journal of Molecular Sciences, 2021, 22, 2537.	4.1	8
131	Development of a Genomic Signatures-Based Predictor of Initial Platinum-Resistance in Advanced High-Grade Serous Ovarian Cancer Patients. Frontiers in Oncology, 2020, 10, 625866.	2.8	10
132	Chimeric Antigen Receptor Design and Efficacy in Ovarian Cancer Treatment. International Journal of Molecular Sciences, 2021, 22, 3495.	4.1	9
133	EIF5A2 enhances stemness of epithelial ovarian cancer cells via a E2F1/KLF4 axis. Stem Cell Research and Therapy, 2021, 12, 186.	5.5	12
134	Prognostic Evidence of the miRNA-Based Ovarian Cancer Signature MiROvaR in Independent Datasets. Cancers, 2021, 13, 1544.	3.7	4
135	Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer. Drug Resistance Updates, 2021, 55, 100744.	14.4	43
136	Pentraxin 3 is a diagnostic and prognostic marker for ovarian epithelial cancer patients based on comprehensive bioinformatics and experiments. Cancer Cell International, 2021, 21, 193.	4.1	10
137	High-grade serous cancer of undetermined primary origin presenting as solitary inguinal lymph node enlargement. BMJ Case Reports, 2021, 14, e239185.	0.5	6
138	European cancer mortality predictions for the year 2021 with focus on pancreatic and female lung cancer. Annals of Oncology, 2021, 32, 478-487.	1.2	98
139	Clinical characteristics and survival outcomes of malignant struma ovarii confined to the ovary. BMC Cancer, 2021, 21, 383.	2.6	17
140	Gallic Acid Induces S and G2 Phase Arrest and Apoptosis in Human Ovarian Cancer Cells In Vitro. Applied Sciences (Switzerland), 2021, 11, 3807.	2.5	4
141	Role of H2B mono-ubiquitination in the initiation and progression of cancer. Bulletin Du Cancer, 2021, 108, 385-398.	1.6	10
142	A radiomics approach for automated diagnosis of ovarian neoplasm malignancy in computed tomography. Scientific Reports, 2021, 11, 8730.	3.3	22
143	A novel immune-related prognostic signature in epithelial ovarian carcinoma. Aging, 2021, 13, 10289-10311.	3.1	8
144	Angiogenesis as a hallmark of solid tumors - clinical perspectives. Cellular Oncology (Dordrecht), 2021, 44, 715-737.	4.4	109
145	Repositioning Trimebutine Maleate as a Cancer Treatment Targeting Ovarian Cancer Stem Cells. Cells, 2021, 10, 918.	4.1	10

#	Article	IF	Citations
146	Ethanol Extracts of Solanum lyratum Thunb Regulate Ovarian Cancer Cell Proliferation, Apoptosis, and Epithelial-to-Mesenchymal Transition (EMT) via the ROS-Mediated p53 Pathway. Journal of Immunology Research, 2021, 2021, 1-16.	2.2	11
147	Quantitative Mass Spectrometry-Based Proteomics for Biomarker Development in Ovarian Cancer. Molecules, 2021, 26, 2674.	3.8	15
148	MRPL15 is a novel prognostic biomarker and therapeutic target for epithelial ovarian cancer. Cancer Medicine, 2021, 10, 3655-3673.	2.8	27
149	Exosomal CD47 Plays an Essential Role in Immune Evasion in Ovarian Cancer. Molecular Cancer Research, 2021, 19, 1583-1595.	3.4	38
150	A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis. International Journal of Molecular Sciences, 2021, 22, 5325.	4.1	16
151	Rs3802278 in 3â€™-UTR of SULF1 associated with platinum resistance and survival in Chinese epithelial ovarian cancer patients. Journal of Chemotherapy, 2021, 33, 1-6.	1.5	0
152	Therapeutic Strategies for Targeting Ovarian Cancer Stem Cells. International Journal of Molecular Sciences, 2021, 22, 5059.	4.1	18
153	Predictive value of RAD51 on the survival and drug responsiveness of ovarian cancer. Cancer Cell International, 2021, 21, 249.	4.1	13
154	Expression and Clinical Significance of Microtubule-Actin Cross-Linking Factor 1 in Serous Ovarian Cancer. Recent Patents on Anti-Cancer Drug Discovery, 2021, 16, 66-72.	1.6	3
155	C/EBPÎ² promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer. Oncogene, 2021, 40, 3845-3858.	5.9	8
156	E74-like factor 3 suppresses microRNA-485-5p transcription to trigger growth and metastasis of ovarian cancer cells with the involvement of CLDN4/Wnt/Î²-catenin axis. Saudi Journal of Biological Sciences, 2021, 28, 4137-4146.	3.8	4
157	Cyclin-dependent kinase 9 (CDK9) predicts recurrence in Middle Eastern epithelial ovarian cancer. Journal of Ovarian Research, 2021, 14, 69.	3.0	5
158	The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives. Clinical Immunology, 2021, 226, 108707.	3.2	127
159	Expression of hormone receptors predicts survival and platinum sensitivity of high-grade serous ovarian cancer. Bioscience Reports, 2021, 41, .	2.4	10
160	Poly (adenosine diphosphate [ADP]â€"ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis. Archives of Gynecology and Obstetrics, 2021, 304, 285-296.	1.7	10
161	Targeting Wnt Signaling in Endometrial Cancer. Cancers, 2021, 13, 2351.	3.7	35
162	Overexpression of RIPK4 Predicts Poor Prognosis and Promotes Metastasis in Ovarian Cancer. BioMed Research International, 2021, 2021, 1-11.	1.9	4
163	The impact of expanding gynecologic oncology care to ovarian cancer patients in small cities and rural communities. Gynecologic Oncology, 2021, 161, 852-857.	1.4	3

#	ARTICLE	IF	CITATIONS
164	A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review). International Journal of Oncology, 2021, 59, .	3.3	66
165	Identification of 5-methylcytosine-related signature for predicting prognosis in ovarian cancer. Biological Research, 2021, 54, 18.	3.4	9
166	Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarianÂcancer. ESMO Open, 2021, 6, 100149.	4.5	19
167	MiR-200b is upregulated in plasma-derived exosomes and functions as an oncogene by promoting macrophage M2 polarization in ovarian cancer. Journal of Ovarian Research, 2021, 14, 74.	3.0	32
168	Chromatin accessibility changes at intergenic regions are associated with ovarian cancer drug resistance. Clinical Epigenetics, 2021, 13, 122.	4.1	7
169	HNRNPH1-stabilized LINC00662 promotes ovarian cancer progression by activating the GRP78/p38 pathway. Oncogene, 2021, 40, 4770-4782.	5.9	10
170	Research Status and Progress of Nutritional Support Therapy for Ovarian Cancer. Nutrition and Cancer, 2022, 74, 1519-1526.	2.0	2
171	CD70 antibodyâ€drug conjugate: A potential novel therapeutic agent for ovarian cancer. Cancer Science, 2021, 112, 3655-3668.	3.9	9
172	High Expression of MYL9 Indicates Poor Clinical Prognosis of Epithelial Ovarian Cancer. Recent Patents on Anti-Cancer Drug Discovery, 2021, 16, 533-539.	1.6	7
173	Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors. Cancers, 2021, 13, 3727.	3.7	13
174	Circular RNA circ_ABCB10 in cancer. Clinica Chimica Acta, 2021, 518, 93-100.	1.1	7
175	Identification of a Novel Tumor Microenvironment Prognostic Signature for Advanced-Stage Serous Ovarian Cancer. Cancers, 2021, 13, 3343.	3.7	14
176	PGK1 Is a Key Target for Anti-Glycolytic Therapy of Ovarian Cancer: Based on the Comprehensive Analysis of Glycolysis-Related Genes. Frontiers in Oncology, 2021, 11, 682461.	2.8	17
177	The lncRNA â€˜UCA1â€™ modulates the response to chemotherapy of ovarian cancer through direct binding to miRâ€27aâ€5p and control of UBE2N levels. Molecular Oncology, 2021, 15, 3659-3678.	4.6	21
178	Lidocaine inhibits the proliferation and metastasis of epithelial ovarian cancer through the Wnt/Î²-catenin pathway. Translational Cancer Research, 2021, 10, 3479-3490.	1.0	9
179	Genome-wide DNA methylome analysis identifies methylation signatures associated with survival and drug resistance of ovarian cancers. Clinical Epigenetics, 2021, 13, 142.	4.1	17
180	Identification and validation of lncRNAs involved in m6A regulation for patients with ovarian cancer. Cancer Cell International, 2021, 21, 363.	4.1	30
181	Recent advancements of antiangiogenic combination therapies in ovarian cancer. Cancer Treatment Reviews, 2021, 98, 102224.	7.7	19

#	Article	IF	Citations
182	Exosomal miR‑21‑5p derived from cisplatin‑resistant SKOV3 ovarian cancer cells promotes glycolysis and inhibits chemosensitivity of its progenitor SKOV3 cells by targeting PDHA1. Cell Biology International, 2021, 45, 2140-2149.	3.0	21
183	Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways. Aging, 2021, 13, 17407-17427.	3.1	14
184	Deregulation of Exo70 Facilitates Innate and Acquired Cisplatin Resistance in Epithelial Ovarian Cancer by Promoting Cisplatin Efflux. Cancers, 2021, 13, 3467.	3.7	9
185	Efficacy and Safety of PARP Inhibitor Combination Therapy in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2021, 11, 638295.	2.8	6
186	Gamma Knife Radiosurgery-Based Combination Treatment Strategies Improve Survival in Patients With Central Nervous System Metastases From Epithelial Ovarian Cancer: A Retrospective Analysis of Two Academic Institutions in Korea and Taiwan. Frontiers in Oncology, 2021, 11, 719936.	2.8	2
187	The Emerging Role of Non-coding RNAs in Drug Resistance of Ovarian Cancer. Frontiers in Genetics, 2021, 12, 693259.	2.3	9
188	Landscape of Immune Microenvironment in Epithelial Ovarian Cancer and Establishing Risk Model by Machine Learning. Journal of Oncology, 2021, 2021, 1-13.	1.3	4
189	TIMELESS Promotes Tumor Progression by Enhancing Macrophages Recruitment in Ovarian Cancer. Frontiers in Oncology, 2021, 11, 732058.	2.8	12
190	Role of sex hormones in modulating breast and ovarian cancer associated pain. Molecular and Cellular Endocrinology, 2021, 533, 111320.	3.2	9
191	lncRNA HIF1A‑AS2: A potential oncogene in human cancers (Review). Biomedical Reports, 2021, 15, 85.	2.0	10
192	Utilizing Patient-Derived Epithelial Ovarian Cancer Tumor Organoids to Predict Carboplatin Resistance. Biomedicines, 2021, 9, 1021.	3.2	13
193	A Novel Classifier Based on Urinary Proteomics for Distinguishing Between Benign and Malignant Ovarian Tumors. Frontiers in Cell and Developmental Biology, 2021, 9, 712196.	3.7	13
194	Effect of molecular targeted agents in chemotherapy for treating platinum-resistant recurrent ovarian cancer. Medicine (United States), 2021, 100, e26849.	1.0	3
195	Amphiregulin increases migration and proliferation of epithelial ovarian cancer cells by inducing its own expression via PI3-kinase signaling. Molecular and Cellular Endocrinology, 2021, 533, 111338.	3.2	6
196	A CLEARER VIEW ON OVARIAN CLEAR CELL CARCINOMA. Acta Clinica Belgica, 2021, , 1-13.	1.2	4
198	The current knowledge concerning solid cancer and therapy. Journal of Biochemical and Molecular Toxicology, 2021, 35, e22900.	3.0	64
199	Folic acid-functionalized tea polyphenol as a tumor-targeting nano-drug delivery system. Materials and Design, 2021, 206, 109805.	7.0	15
200	Scutellarein induces apoptosis and inhibits proliferation, migration, and invasion in ovarian cancer via inhibition of EZH2/FOXO1 signaling. Journal of Biochemical and Molecular Toxicology, 2021, 35, e22870.	3.0	11

#	Article	IF	Citations
201	Loss of Krüppel-like factor 9 facilitates stemness in ovarian cancer ascites-derived multicellular spheroids via Notch1/slug signaling. Cancer Science, 2021, 112, 4220-4233.	3.9	8
202	Treatment Experience and Predictive Factors Associated with Response in Platinum-Resistant Recurrent Ovarian Cancer: A Retrospective Single-Institution Study. Journal of Clinical Medicine, 2021, 10, 3596.	2.4	1
203	CXCL2-mediated ATR/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancer. Journal of Ovarian Research, 2021, 14, 115.	3.0	6
204	Dual mTORC1/2 inhibitor AZD2014 diminishes myeloid-derived suppressor cells accumulation in ovarian cancer and delays tumor growth. Cancer Letters, 2021, 523, 72-81.	7.2	12
205	Diagnosis of Ovarian Neoplasms Using Nomogram in Combination With Ultrasound Image-Based Radiomics Signature and Clinical Factors. Frontiers in Genetics, 2021, 12, 753948.	2.3	17
206	Significance of glutathione peroxidase 4 and intracellular iron level in ovarian cancer cells—"utilization" of ferroptosis mechanism. Inflammation Research, 2021, 70, 1177-1189.	4.0	15
207	Calcineurin Gamma Catalytic Subunit PPP3CC Inhibition by miR-200c-3p Affects Apoptosis in Epithelial Ovarian Cancer. Genes, 2021, 12, 1400.	2.4	4
208	Knockdown of DLGAP5 suppresses cell proliferation, induces G_2/M phase arrest and apoptosis in ovarian cancer. Experimental and Therapeutic Medicine, 2021, 22, 1245.	1.8	14
209	Synthetic Lethality in Ovarian Cancer. Molecular Cancer Therapeutics, 2021, 20, 2117-2128.	4.1	20
210	Propofol-Based Total Intravenous Anesthesia is Associated with Better Survival than Desflurane Anesthesia in Epithelial Ovarian Cancer Surgery: A Retrospective Cohort Study. Frontiers in Pharmacology, 2021, 12, 685265.	3.5	5
211	Arsenic compound sensitizes homologous recombination proficient ovarian cancer to PARP inhibitors. Cell Death Discovery, 2021, 7, 259.	4.7	8
212	Caseinolytic protease P (CLPP) activated by ONC201 inhibits proliferation and promotes apoptosis in human epithelial ovarian cancer cells by inducing mitochondrial dysfunction. Annals of Translational Medicine, 2021, 9, 1463-1463.	1.7	3
213	The Stress-Inducible BCL2A1 Is Required for Ovarian Cancer Metastatic Progression in the Peritoneal Microenvironment. Cancers, 2021, 13, 4577.	3.7	6
214	Novel Anti-Angiogenic and Anti-Tumour Activities of the N-Terminal Domain of NOEY2 via Binding to VEGFR-2 in Ovarian Cancer. Biomolecules and Therapeutics, 2021, 29, 506-518.	2.4	5
215	Construction and Validation of a Platinum Sensitivity Predictive Model With Multiple Genomic Variations for Epithelial Ovarian Cancer. Frontiers in Oncology, 2021, 11, 725264.	2.8	8
216	Comprehensive analysis of LASS6 expression and prognostic value in ovarian cancer. Journal of Ovarian Research, 2021, 14, 117.	3.0	2
217	Human papillomavirus and ovarian cancer (review of literature and meta-analysis). Infection, Genetics and Evolution, 2021, 95, 105086.	2.3	4
218	Screening ovarian cancers with Raman spectroscopy of blood plasma coupled with machine learning data processing. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2022, 265, 120355.	3.9	20

#	Article	IF	Citations
220	LncRNA NEAT1 promotes proliferation of ovarian cancer cells and angiogenesis of co-incubated human umbilical vein endothelial cells by regulating FGF9 through sponging miR-365. Medicine (United) Tj ETQq0 0.0 rgBT /Overlock 10	0.0	10
221	Optimization of aptamer selection on an automated microfluidic system with cancer tissues. Lab on A Chip, 2021, 21, 725-734.	6.0	15
223	EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression. Clinical Cancer Research, 2020, 26, 4206-4215.	7.0	84
224	Dysregulation of pseudogene/lncRNA-hsa-miR-363-3p-SPOCK2 pathway fuels stage progression of ovarian cancer. Aging, 2019, 11, 11416-11439.	3.1	43
225	Overexpressed ITGA2 contributes to paclitaxel resistance by ovarian cancer cells through the activation of the AKT/FoxO1 pathway. Aging, 2020, 12, 5336-5351.	3.1	35
226	Immune profiling reveals prognostic genes in high-grade serous ovarian cancer. Aging, 2020, 12, 11398-11415.	3.1	12
227	circKIF4A sponges miR-127 to promote ovarian cancer progression. Aging, 2020, 12, 17921-17929.	3.1	15
228	Construction of a new tumor immunity-related signature to assess and classify the prognostic risk of ovarian cancer. Aging, 2020, 12, 21316-21328.	3.1	6
229	Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going?. Annals of Translational Medicine, 2020, 8, 1710-1710.	1.7	35
230	Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance. Current Drug Targets, 2020, 21, 167-178.	2.1	10
231	Expression and clinical significance of methylâ€‘CpG binding domain protein 2 in highâ€‘grade serous ovarian cancer. Oncology Letters, 2020, 20, 2749-2756.	1.8	7
232	TIPE1 impairs ovarian tumor growth by promoting caspase-dependent apoptosis. Oncology Letters, 2020, 20, 1-1.	1.8	7
233	Characterization of ovarian cancer-derived extracellular vesicles by surface-enhanced Raman spectroscopy. Analyst, The, 2021, 146, 7194-7206.	3.5	13
234	Origins and Pathology of Epithelial Ovarian Cancer: A Brief Overview. , 2021, , 1-17.		0
235	â€œPincer movementâ€: Reversing cisplatin resistance based on simultaneous glutathione depletion and glutathione S-transferases inhibition by redox-responsive degradable organosilica hybrid nanoparticles. Acta Pharmaceutica Sinica B, 2022, 12, 2074-2088.	12.0	14
236	Application of Bioinformatics Analysis to Identify Important Pathways and Hub Genes in Ovarian Cancer Affected by WT1. Frontiers in Bioengineering and Biotechnology, 2021, 9, 741051.	4.1	4
237	Significance of TEAD Family in Diagnosis, Prognosis and Immune Response for Ovarian Serous Carcinoma. International Journal of General Medicine, 2021, Volume 14, 7133-7143.	1.8	8
238	Global, regional, and national burden of ovarian cancer and the attributable risk factors in all 194 countries and territories during 2007â€"2017: A systematic analysis of the Global Burden of Disease Study 2017. Journal of Obstetrics and Gynaecology Research, 2021, 47, 4389-4402.	1.3	2

#	Article	IF	Citations
239	AHNAK suppresses ovarian cancer progression through the Wnt/Î²-catenin signaling pathway. Aging, 2021, 13, 23579-23587.	3.1	14
240	High-Fat Diet-Induced Obese Effects of Adipocyte-Specific CXCR2 Conditional Knockout in the Peritoneal Tumor Microenvironment of Ovarian Cancer. Cancers, 2021, 13, 5033.	3.7	3
241	MiR-149-5p: An Important miRNA Regulated by Competing Endogenous RNAs in Diverse Human Cancers. Frontiers in Oncology, 2021, 11, 743077.	2.8	7
243	Role of integrins in the metastatic spread of high-grade serous ovarian cancer. Archives of Gynecology and Obstetrics, 2021, , 1.	1.7	3
244	Circulating non-coding RNAs in recurrent and metastatic ovarian cancer. , 2019, 2, 399-418.		2
245	Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy. Cancer Communications, 2021, 41, 1331-1353.	9.2	48
246	Prognostic value of preoperative soluble interleukin 2 receptor Î± as a novel immune biomarker in epithelial ovarian cancer. Cancer Immunology, Immunotherapy, 2022, 71, 1519-1530.	4.2	1
247	LIM domain-containing 2 (LIMD2) promotes the progress of ovarian cancer via the focal adhesion signaling pathway. Bioengineered, 2021, 12, 10089-10100.	3.2	5
248	Exosomal ANXA2 derived from ovarian cancer cells regulates epithelialâ€mesenchymal plasticity of human peritoneal mesothelial cells. Journal of Cellular and Molecular Medicine, 2021, 25, 10916-10929.	3.6	21
249	A Comprehensive Molecular and Clinical Analysis of the piRNA Pathway Genes in Ovarian Cancer. Cancers, 2021, 13, 4.	3.7	9
250	Mitochondrial Dynamics Mediated by DRP1 and MFN2 Contributes to Cisplatin Chemoresistance in Human Ovarian Cancer SKOV3 cells. Journal of Cancer, 2021, 12, 7358-7373.	2.5	18
251	The anti-tumor effect of OP-B on ovarian cancer in vitro and in vivo, and its mechanism: An investigation using network pharmacology-based analysis. Journal of Ethnopharmacology, 2022, 283, 114706.	4.1	6
252	An improved YOLOv3 model for detecting location information of ovarian cancer from CT images. Intelligent Data Analysis, 2021, 25, 1565-1578.	0.9	6
253	Immune Cell Infiltration Landscape of Ovarian Cancer to Identify Prognosis and Immunotherapy-Related Genes to Aid Immunotherapy. Frontiers in Cell and Developmental Biology, 2021, 9, 749157.	3.7	6
255	SRT2183 impairs ovarian cancer by facilitating autophagy. Aging, 2020, 12, 24208-24218.	3.1	8
256	mTOR inhibition overcomes primary and acquired resistance to Wee1 inhibition by augmenting replication stress in epithelial ovarian cancers. American Journal of Cancer Research, 2020, 10, 908-924.	1.4	3
257	Identification of SOCS family members with prognostic values in human ovarian cancer. American Journal of Translational Research (discontinued), 2020, 12, 1824-1838.	0.0	7
258	Treatment algorithm in patients with ovarian cancer. Facts, Views & Vision in ObGyn, 2020, 12, 227-239.	1.1	2

#	Article	IF	Citations
259	Interactions between tumor mutation burden and immune infiltration in ovarian cancer. International Journal of Clinical and Experimental Pathology, 2020, 13, 2513-2523.	0.5	2
260	The inhibition of BRAF activity sensitizes chemoresistant human ovarian cancer cells to paclitaxel-induced cytotoxicity and tumor growth inhibition. American Journal of Translational Research (discontinued), 2020, 12, 8084-8098.	0.0	5
261	Tumor-derived exosomal circRNA051239 promotes proliferation and migration of epithelial ovarian cancer. American Journal of Translational Research (discontinued), 2021, 13, 1125-1139.	0.0	8
262	Diagnostic Value of Serum Markers Combined with TVCDS in Ovarian Cancer Patients Treated with Bushen Yiqi Quyu Prescription. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-7.	1.2	0
263	Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. Frontiers in Oncology, 2021, 11, 785102.	2.8	4
264	Improving the quality of care for patients with advanced epithelial ovarian cancer: Program components, implementation barriers, and recommendations. Cancer, 2022, 128, 654-664.	4.1	10
265	LINC00641 inhibits the proliferation and invasion of ovarian cancer cells by targeting miR-320a. Translational Cancer Research, 2021, 10, 4894-4904.	1.0	1
266	Peritoneal Modulators of Endometriosis-Associated Ovarian Cancer. Frontiers in Oncology, 2021, 11, 793297.	2.8	4
267	Endometriosis-associated epithelial ovarian cancer is a more complicated disease than we suspected before. Taiwanese Journal of Obstetrics and Gynecology, 2021, 60, 1112-1115.	1.3	6
268	Application of Dynamic and Static Light Scattering for Size and Shape Characterization of Small Extracellular Nanoparticles in Plasma and Ascites of Ovarian Cancer Patients. International Journal of Molecular Sciences, 2021, 22, 12946.	4.1	9
269	Nomogram for predicting postoperative cancer-specific early death in patients with epithelial ovarian cancer based on the SEER database: a large cohort study. Archives of Gynecology and Obstetrics, 2022, 305, 1535-1549.	1.7	3
270	Comprehensive Analysis of the Tumor Microenvironment and Ferroptosis-Related Genes Predict Prognosis with Ovarian Cancer. Frontiers in Genetics, 2021, 12, 774400.	2.3	6
271	Circulating tumor DNA: a noninvasive biomarker for tracking ovarian cancer. Reproductive Biology and Endocrinology, 2021, 19, 178.	3.3	17
272	The Emerging Roles of Ï€ Subunit-Containing GABA$_A$ Receptors in Different Cancers. International Journal of Medical Sciences, 2021, 18, 3851-3860.	2.5	7
274	Exosome-based rare earth nanoparticles for targeted *in situ* and metastatic tumor imaging with chemo-assisted immunotherapy. Biomaterials Science, 2022, 10, 744-752.	5.4	5
275	Immuno-genomic characterisation of high-grade serous ovarian cancer reveals immune evasion mechanisms and identifies an immunological subtype with a favourable prognosis and improved therapeutic efficacy. British Journal of Cancer, 2022, 126, 1570-1580.	6.4	18
276	Basics of immunotherapy for epithelial ovarian cancer. Journal of Gynecology Obstetrics and Human Reproduction, 2022, 51, 102283.	1.3	4
278	Immune-Related Long Non-coding RNA Constructs a Prognostic Signature of Ovarian Cancer. Biological Procedures Online, 2021, 23, 24.	2.9	5

#	Article	IF	Citations
279	Integrated clinical characteristics and omics analysis identifies a ferroptosis and iron-metabolism-related lncRNA signature for predicting prognosis and therapeutic responses in ovarian cancer. Journal of Ovarian Research, 2022, 15, 10.	3.0	36
280	A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer. Journal of Ovarian Research, 2022, 15, 8.	3.0	12
281	Beyond BRCA1/2: Homologous Recombination Repair Genetic Profile in a Large Cohort of Apulian Ovarian Cancers. Cancers, 2022, 14, 365.	3.7	5
282	An Insight into miR-1290: An Oncogenic miRNA with Diagnostic Potential. International Journal of Molecular Sciences, 2022, 23, 1234.	4.1	12
283	Fibrinogen/albumin ratio as a promising predictor of platinum response and survival in ovarian clear cell carcinoma. BMC Cancer, 2022, 22, 92.	2.6	8
284	Biocompatible micro tweezers for 3D hydrogel organoid array mechanical characterization. PLoS ONE, 2022, 17, e0262950.	2.5	2
285	Clinical significance of metabolism-related genes and FAK activity in ovarian high-grade serous carcinoma. BMC Cancer, 2022, 22, 59.	2.6	3
286	Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer. Journal of Nanobiotechnology, 2022, 20, 50.	9.1	66
287	Validation of MiROvaR, a microRNA-based predictor of early relapse in early stage epithelial ovarian cancer as a new strategy to optimise patients' prognostic assessment. European Journal of Cancer, 2022, 161, 55-63.	2.8	3
288	Extracellular vesicles in ovarian cancer chemoresistance, metastasis, and immune evasion. Cell Death and Disease, 2022, 13, 64.	6.3	50
289	TIL expansion with high dose IL-2 or low dose IL-2 with anti-CD3/anti-CD28 stimulation provides different quality of TIL-expanded T cell clones. Journal of Immunological Methods, 2022, 503, 113229.	1.4	3
290	PD-L1 near Infrared Photoimmunotherapy of Ovarian Cancer Model. Cancers, 2022, 14, 619.	3.7	4
291	Acquisition of taxane resistance by p53 inactivation in ovarian cancer cells. Acta Pharmacologica Sinica, 2022, , .	6.1	4
292	Phenethyl Isothiocyanate Enhances the Cytotoxic Effects of PARP Inhibitors in High-Grade Serous Ovarian Cancer Cells. Frontiers in Oncology, 2021, 11, 812264.	2.8	6
293	Comprehensive Analysis of CRIP1 in Patients with Ovarian Cancer, including ceRNA Network, Immune-Infiltration Pattern, and Clinical Benefit. Disease Markers, 2022, 2022, 1-11.	1.3	1
294	The Immunological Role of CDK4/6 and Potential Mechanism Exploration in Ovarian Cancer. Frontiers in Immunology, 2021, 12, 799171.	4.8	6
295	Oleanolic Acid (OA) Targeting UNC5B Inhibits Proliferation and EMT of Ovarian Cancer Cell and Increases Chemotherapy Sensitivity of Niraparib. Journal of Oncology, 2022, 2022, 1-12.	1.3	2
296	GOLM1 as a Potential Therapeutic Target Modulates B7-H3 Secretion to Drive Ovarian Cancer Metastasis. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-12.	1.2	1

#	ARTICLE	IF	CITATIONS
297	OSI-906 restores the sensitivity of ovarian clear cell carcinoma to cisplatin by targeting the IGF1R/AKT pathway. Medical Oncology, 2022, 39, 26.	2.5	3
298	Histopathological whole slide image dataset for classification of treatment effectiveness to ovarian cancer. Scientific Data, 2022, 9, 25.	5.3	7
299	Heterogeneity of EpCAM-positive cells in low-grade serous ovarian carcinoma ascitic fluid: a clinical case. Opuholi Zenskoj Reproduktivnoj Sistemy, 2022, 17, 90-95.	0.4	2
300	Stichoposide C Exerts Anticancer Effects on Ovarian Cancer by Inducing Autophagy via Inhibiting AKT/mTOR Pathway. OncoTargets and Therapy, 2022, Volume 15, 87-101.	2.0	6
301	Survival and prognostic factors in women treated for epithelial ovarian cancer in western region of Saudi Arabia. Journal of King Abdulaziz University, Islamic Economics, 2022, 43, 146-155.	1.1	0
302	High expression of TRIM24 predicts worse prognosis and promotes proliferation and metastasis of epithelial ovarian cancer. Journal of Ovarian Research, 2022, 15, 19.	3.0	9
303	KHDRBS3 promotes paclitaxel resistance and induces glycolysis through modulated MIR17HG/CLDN6 signaling in epithelial ovarian cancer. Life Sciences, 2022, 293, 120328.	4.3	15
304	Histological Grade and Tumor Stage Are Correlated with Expression of Receptor Activator of Nuclear Factor Kappa b (Rank) in Epithelial Ovarian Cancers. International Journal of Molecular Sciences, 2022, 23, 1742.	4.1	0
305	HDAC9 Contributes to Serous Ovarian Cancer Progression through Regulating Epithelialâ€"Mesenchymal Transition. Biomedicines, 2022, 10, 374.	3.2	8
306	Co-Overexpression of GRK5/ACTC1 Correlates With the Clinical Parameters and Poor Prognosis of Epithelial Ovarian Cancer. Frontiers in Molecular Biosciences, 2021, 8, 785922.	3.5	3
307	Primary and metastatic peritoneal surface malignancies. Nature Reviews Disease Primers, 2021, 7, 91.	30.5	87
308	Second primary malignancies after ovarian cancer: A SEER-based analysis (1975â€"2016). Taiwanese Journal of Obstetrics and Gynecology, 2022, 61, 80-85.	1.3	6
309	Nanomaterial-based biosensor developing as a route toward in vitro diagnosis of early ovarian cancer. Materials Today Bio, 2022, 13, 100218.	5.5	23
310	Carrier-free multifunctional nanomedicine for intraperitoneal disseminated ovarian cancer therapy. Journal of Nanobiotechnology, 2022, 20, 93.	9.1	18
311	USP13 promotes development and metastasis of high-grade serous ovarian carcinoma in a novel mouse model. Oncogene, 2022, 41, 1974-1985.	5.9	9
312	Identification of a novel <scp>nineâ€‘snoRNA</scp> signature with potential prognostic and therapeutic value in ovarian cancer. Cancer Medicine, 2022, , .	2.8	6
313	Sporoderm-Broken Spores of Ganoderma lucidum Sensitizes Ovarian Cancer to Cisplatin by ROS/ERK Signaling and Attenuates Chemotherapy-Related Toxicity. Frontiers in Pharmacology, 2022, 13, 826716.	3.5	7
315	Expression of Enhancer-Binding Protein CEBPA mRNA and Protein in Ovarian Cancer and Its Relationship With Pathobiological Characteristics. Frontiers in Surgery, 2022, 9, 842823.	1.4	2

#	ARTICLE	IF	CITATIONS
316	SCNN1A Overexpression Correlates with Poor Prognosis and Immune Infiltrates in Ovarian Cancer. International Journal of General Medicine, 2022, Volume 15, 1743-1763.	1.8	2
317	Principles of dormancy evident in high-grade serous ovarian cancer. Cell Division, 2022, 17, 2.	2.4	10
318	Establish of an Initial Platinum-Resistance Predictor in High-Grade Serous Ovarian Cancer Patients Regardless of Homologous Recombination Deficiency Status. Frontiers in Oncology, 2022, 12, 847085.	2.8	3
319	Clinical Efficacy of Yiqi Yangyin Decoction Combined with Docetaxel on Advanced Ovarian Cancer and the Effect on the Levels of Serum Markers VEGF, HE4, and CA125. Journal of Healthcare Engineering, 2022, 2022, 1-7.	1.9	4
320	Association Between Endometriosis and Prognosis of Ovarian Cancer: An Updated Meta-Analysis. Frontiers in Oncology, 2022, 12, 732322.	2.8	6
321	Serum Autoantibodies against LRDD, STC1, and FOXA1 as Biomarkers in the Detection of Ovarian Cancer. Disease Markers, 2022, 2022, 1-11.	1.3	6
322	RIPK4 Is an Immune Regulating-Associated Biomarker for Ovarian Cancer and Possesses Generalization Value in Pan-Cancer. Journal of Immunology Research, 2022, 2022, 1-21.	2.2	1
323	Elaboration of novel urea bearing schiff bases as potent inÂvitro anticancer candidates with low inÂvivo acute oral toxicity. Main Group Chemistry, 2022, , 1-19.	0.8	4
324	Involvement of Cancer Stem Cells in Chemoresistant Relapse of Epithelial Ovarian Cancer Identified by Transcriptome Analysis. Journal of Oncology, 2022, 2022, 1-16.	1.3	1
325	Extracellular Vesicles from Uterine Aspirates Represent a Promising Source for Screening Markers of Gynecologic Cancers. Cells, 2022, 11, 1064.	4.1	7
326	Fertility Sparing Surgery and Borderline Ovarian Tumours. Cancers, 2022, 14, 1485.	3.7	8
327	Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin. Frontiers in Medicine, 2022, 9, 807377.	2.6	2
328	Cancer-inducing niche: the force of chronic inflammation. British Journal of Cancer, 2022, 127, 193-201.	6.4	40
329	RNA 5-Methylcytosine Regulators Contribute to Metabolism Heterogeneity and Predict Prognosis in Ovarian Cancer. Frontiers in Cell and Developmental Biology, 2022, 10, 807786.	3.7	7
330	Immune Subtypes Characterization Identifies Clinical Prognosis, Tumor Microenvironment Infiltration, and Immune Response in Ovarian Cancer. Frontiers in Molecular Biosciences, 2022, 9, 801156.	3.5	0
331	Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer. Molecular Cancer Therapeutics, 2022, 21, 1030-1043.	4.1	6
332	RB1 Is an Immune-Related Prognostic Biomarker for Ovarian Cancer. Frontiers in Oncology, 2022, 12, 830908.	2.8	6
333	Efficacy and Pharmacological Mechanism of Poria cocos-Based Formulas Combined With Chemotherapy for Ovarian Cancer: A Integrated Systems Pharmacology Study. Frontiers in Pharmacology, 2022, 13, 788810.	3.5	3

#	ARTICLE	IF	CITATIONS
334	Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: Pre-clinical updates. Oncotarget, 2022, 13, 553-575.	1.8	6
335	Stanniocalcin 1 promotes metastasis, lipid metabolism and cisplatin chemoresistance via the FOXC2/ITGB6 signaling axis in ovarian cancer. Journal of Experimental and Clinical Cancer Research, 2022, 41, 129.	8.6	35
336	Sonosensitizer nanoplatform-mediated sonodynamic therapy induced immunogenic cell death and tumor immune microenvironment variation. Drug Delivery, 2022, 29, 1164-1175.	5.7	14
337	Health Care Resource Utilization and Costs Associated with Disease Progression in Ovarian Cancer. Advances in Therapy, 2022, 39, 2544-2561.	2.9	4
338	The Peptide-Drug Conjugate TH1902: A New Sortilin Receptor-Mediated Cancer Therapeutic against Ovarian and Endometrial Cancers. Cancers, 2022, 14, 1877.	3.7	10
339	Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells. Cancers, 2022, 14, 1807.	3.7	10
340	LINC00339: An emerging major player in cancer and metabolic diseases. Biomedicine and Pharmacotherapy, 2022, 149, 112788.	5.6	6
341	Development of a radiomic–clinical nomogram for prediction of survival in patients with serous ovarian cancer. Clinical Radiology, 2022, 77, 352-359.	1.1	11
342	With Our Powers Combined. Cancer Journal (Sudbury, Mass), 2021, 27, 511-520.	2.0	1
343	Effective Disease Control After Combinatorial Treatment with a PD-1 Antibody and an mTOR Inhibitor for Recurrent Ovarian Clear Cell Carcinomas: A Case Report and Literature Review. OncoTargets and Therapy, 2021, Volume 14, 5429-5434.	2.0	3
344	tRNAGlyGCC-Derived Internal Fragment (i-tRF-GlyGCC) in Ovarian Cancer Treatment Outcome and Progression. Cancers, 2022, 14, 24.	3.7	25
345	Proteomic Analysis Reveals Low-Dose PARP Inhibitor-Induced Differential Protein Expression in BRCA1-Mutated High-Grade Serous Ovarian Cancer Cells. Journal of the American Society for Mass Spectrometry, 2022, 33, 242-250.	2.8	5
346	A novel targeted co-delivery nanosystem for enhanced ovarian cancer treatment via multidrug resistance reversion and mTOR-mediated signaling pathway. Journal of Nanobiotechnology, 2021, 19, 444.	9.1	16
347	Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer. Biomedicines, 2022, 10, 77.	3.2	12
348	Cisplatin Resistance in Ovarian Cancer: Classical Outlook and Newer Perspectives. Biomedical and Pharmacology Journal, 2021, 14, 1993-2005.	0.5	4
349	The Role of TRIP6, ABCC3 and CPS1 Expression in Resistance of Ovarian Cancer to Taxanes. International Journal of Molecular Sciences, 2022, 23, 73.	4.1	7
350	Role of Mitochondria in Interplay between NGF/TRKA, miR-145 and Possible Therapeutic Strategies for Epithelial Ovarian Cancer. Life, 2022, 12, 8.	2.4	7
351	Plant-Derived Chinese Medicine Monomers on Ovarian Cancer via the Wnt/Î²-Catenin Signaling Pathway: Review of Mechanisms and Prospects. Journal of Oncology, 2021, 2021, 1-10.	1.3	6

#	Article	IF	Citations
352	Nelfinavir Induces Cytotoxicity towards High-Grade Serous Ovarian Cancer Cells, Involving Induction of the Unfolded Protein Response, Modulation of Protein Synthesis, DNA Damage, Lysosomal Impairment, and Potentiation of Toxicity Caused by Proteasome Inhibition. Cancers, 2022, 14, 99.	3.7	3
353	Deep Learning Prediction of Ovarian Malignancy at US Compared with O-RADS and Expert Assessment. Radiology, 2022, 304, 106-113.	7.3	23
354	Pre-diagnosis Dietary One-Carbon Metabolism Micronutrients Consumption and Ovarian Cancer Survival: A Prospective Cohort Study. Frontiers in Nutrition, 2022, 9, 873249.	3.7	5
355	Phosphate dysregulation via the XPR1â€"KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer. Nature Cancer, 2022, 3, 681-695.	13.2	21
360	Genomic and TCR profiling data reveal the distinct molecular traits in epithelial ovarian cancer histotypes. Oncogene, 2022, 41, 3093-3103.	5.9	7
361	Applications of artificial intelligence (AI) in ovarian cancer, pancreatic cancer, and image biomarker discovery. Cancer Biomarkers, 2022, 33, 173-184.	1.7	7
362	CD105 expression is associated with invasive capacity in ovarian cancer and promotes invasiveness by inhibiting NDRG1 and regulating the epithelial-mesenchymal transition.. American Journal of Translational Research (discontinued), 2021, 13, 12461-12479.	0.0	0
363	Metastatic Ovarian Mucinous Carcinoma Presenting as Ileocecal Adenocarcinoma: A Case Report. Cureus, 2022, , .	0.5	0
364	Discovery of Natural Ursane-type SENP1 Inhibitors and the Platinum Resistance Reversal Activity Against Human Ovarian Cancer Cells: A Structureâ€"Activity Relationship Study. Journal of Natural Products, 2022, 85, 1248-1255.	3.0	4
365	Four Types of RNA Modification Writer-Related lncRNAs Are Effective Predictors of Prognosis and Immunotherapy Response in Serous Ovarian Carcinoma. Frontiers in Immunology, 2022, 13, 863484.	4.8	7
366	MiR-320b and miR-320d as Biomarkers to Predict and Participate in the Formation of Platinum Resistance in Ovarian Cancer Patients. Frontiers in Oncology, 2022, 12, 881496.	2.8	6
367	Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer. Cancer Research Communications, 2022, 2, 293-306.	1.7	4
368	Applications of Proteomics in Ovarian Cancer: Dawn of a New Era. Proteomes, 2022, 10, 16.	3.5	66
369	Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study. Gynecologic Oncology, 2022, 166, 36-43.	1.4	18
370	The Emerging Roles and Therapeutic Implications of Epigenetic Modifications in Ovarian Cancer. Frontiers in Endocrinology, 2022, 13, .	3.5	6
371	A risk score system based on a six-microRNA signature predicts the overall survival of patients with ovarian cancer. Journal of Ovarian Research, 2022, 15, 54.	3.0	4
372	The Effect of Bone Marrow Mesenchymal Stem Cells-Exosomes (BMSC-EXO) on Tumor Angiogenesis and Its Mechanism in Ovarian Cancer Microenvironment. Journal of Biomaterials and Tissue Engineering, 2022, 12, 1087-1094.	0.1	0
373	Ovarian cancer detection using optimized machine learning models with adaptive differential evolution. Biomedical Signal Processing and Control, 2022, 77, 103785.	5.7	5

#	ARTICLE	IF	CITATIONS
374	The enhancer RNA ADCY10P1 is associated with the progression of ovarian cancer. Journal of Ovarian Research, 2022, 15, 61.	3.0	5
375	Impact of Adjuvant Chemotherapy on FIGO Stage I Ovarian Clear Cell Carcinoma: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2022, 12, .	2.8	5
376	Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210950.	3.2	0
377	Identification of CD8+ T Cell Related Biomarkers in Ovarian Cancer. Frontiers in Genetics, 0, 13, .	2.3	5
378	SOCS7/HuR/FOXM1 signaling axis inhibited high-grade serous ovarian carcinoma progression. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	8.6	2
379	MCM10 is a Prognostic Biomarker and Correlated With Immune Checkpoints in Ovarian Cancer. Frontiers in Genetics, 0, 13, .	2.3	5
380	Fluorochrome Selection for Imaging Intraoperative Ovarian Cancer Probes. Pharmaceuticals, 2022, 15, 668.	3.8	5
382	Alantolactone-Loaded Pegylated Prodrug Nanocarriers for Synergistic Treatment of Cisplatin-Resistant Ovarian Cancer via Reactivating Mitochondrial Apoptotic Pathway. ACS Biomaterials Science and Engineering, 2022, 8, 2526-2536.	5.2	2
383	Non-Coding RNAs Delivery by Small Extracellular Vesicles and Their Applications in Ovarian Cancer. Frontiers in Bioengineering and Biotechnology, 2022, 10, .	4.1	2
384	Sintilimab combined with bevacizumab in relapsed/persistent ovarian clear cell carcinoma (INOVA): an investigator-initiated, multicentre clinical trialâ€"a study protocol of clinical trial. BMJ Open, 2022, 12, e058132.	1.9	1
385	Comprehensive Network Analysis of Dysregulated Genes Revealed MNX1â€AS1/ hsaâ€miRâ€4697â€3p/ HOXB13 Axis in OC Chemotherapy Response. Cancer Science, 0, , .	3.9	4
386	Identification and Validation of the Diagnostic Characteristic Genes of Ovarian Cancer by Bioinformatics and Machine Learning. Frontiers in Genetics, 0, 13, .	2.3	4
387	Mutation profiles in circulating cellâ€free <scp>DNA</scp> predict acquired resistance to Olaparib in highâ€grade serous ovarian carcinoma. Cancer Science, 0, , .	3.9	5
388	Spheroid Formation and Peritoneal Metastasis in Ovarian Cancer: The Role of Stromal and Immune Components. International Journal of Molecular Sciences, 2022, 23, 6215.	4.1	12
389	MEX3A promotes the malignant progression of ovarian cancer by regulating intron retention in TIMELESS. Cell Death and Disease, 2022, 13, .	6.3	12
390	Metagenomic analysis of the microbiome of the upper reproductive tract: combating ovarian cancer through predictive, preventive, and personalized medicine. EPMA Journal, 2022, 13, 487-498.	6.1	4
391	CXCR4 knockdown enhances sensitivity of paclitaxel via the PI3K/Akt/mTOR pathway in ovarian carcinoma. Aging, 2022, 14, 4673-4698.	3.1	6
392	Detection of ovarian cancer using plasma cell-free DNA methylomes. Clinical Epigenetics, 2022, 14, .	4.1	10

#	ARTICLE	IF	CITATIONS
393	A compound formulation of EGF-modified paclitaxel micelles and EGF-modified emodin micelles enhance the therapeutic effect of ovarian cancer. Journal of Liposome Research, 2023, 33, 89-101.	3.3	4
394	Identification and clinical validation of NUSAP1 as a novel prognostic biomarker in ovarian cancer. BMC Cancer, 2022, 22, .	2.6	4
395	Identification and Verification of Necroptosis-Related Gene Signature With Prognosis and Tumor Immune Microenvironment in Ovarian Cancer. Frontiers in Immunology, 0, 13, .	4.8	6
396	Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Ovarian Cancer: A Systematic Review and Network Meta-Analysis. Frontiers in Oncology, 0, 12, .	2.8	8
397	The Expression and Role Analysis of Methylation-Regulated Differentially Expressed Gene UBE2C in Pan-Cancer, Especially for HGSOC. Cancers, 2022, 14, 3121.	3.7	1
398	Somatic genomic landscape of East Asian epithelial ovarian carcinoma and its clinical implications from prospective clinical sequencing: A Korean Gynecologic Oncology Group study (<scp>KGOG</scp>) Tj ETQq1 1 0.784314 rgBT /Ove		
399	A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers. Current Oncology, 2022, 29, 4354-4369.	2.2	1
400	The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta‐analysis. International Journal of Cancer, 2022, 151, 1626-1639.	5.1	8
401	Humanized Ovarian Cancer Patient-Derived Xenografts for Improved Preclinical Evaluation of Immunotherapies. Cancers, 2022, 14, 3092.	3.7	5
402	The value of Copenhagen Index in the diagnosis of malignant adnexal tumors: a meta‐analysis. International Journal of Gynecology and Obstetrics, 0, , .	2.3	1
403	Hyperthermia synergistically enhances antitumor efficacy of PARP inhibitor through impacting homologous recombination repair and oxidative stress inÂvitro. Biochemical and Biophysical Research Communications, 2022, 619, 49-55.	2.1	1
404	miRNA-651-3p regulates EMT in ovarian cancer cells by targeting ZNF703 and via the MEK/ERK pathway. Biochemical and Biophysical Research Communications, 2022, 619, 76-83.	2.1	6
405	EOCSA: Predicting prognosis of Epithelial ovarian cancer with whole slide histopathological images. Expert Systems With Applications, 2022, 206, 117643.	7.6	8
406	The tumor immune microenvironment in peritoneal carcinomatosis. International Review of Cell and Molecular Biology, 2022, , 63-95.	3.2	6
407	Effects of Agarum clathratum extract on cell death and calcium ion levels of ovarian cancer cell. Molecular and Cellular Toxicology, 2023, 19, 303-310.	1.7	7
408	An Effective Hormonal Therapy for a Patient with Estrogen Receptor 1 (ESR1)-Amplified Metastatic Ovarian Cancer: A Case Report. OncoTargets and Therapy, 0, Volume 15, 643-649.	2.0	3
409	Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer: A Belgian expert opinion. Facts, Views & Vision in ObGyn, 2022, 14, 111-120.	1.1	1
410	The Evaluation Value of CT in the Efficacy of Neoadjuvant Chemotherapy in Ovarian Cancer Patients. Contrast Media and Molecular Imaging, 2022, 2022, 1-8.	0.8	2

#	Article	IF	Citations
411	Targeted peptide-modified oxidized mesoporous carbon nanospheres for chemo-thermo combined therapy of ovarian cancer <i>in vitro</i>. Drug Delivery, 2022, 29, 1951-1958.	5.7	5
412	Anticancer Potential of Cinnamon Bark Extract (Cinnamomum burmanii) with Cisplatin Combination against P-glycoprotein and Apoptotic Influx Biomarkers. Open Access Macedonian Journal of Medical Sciences, 2022, 10, 958-964.	0.2	0
413	Role of the Glyoxalase System in Breast Cancer and Gynecological Cancer-Implications for Therapeutic Intervention: a Review. Frontiers in Oncology, 0, 12, .	2.8	4
414	Glaucocalyxin A Inhibits the Malignant Progression of Epithelial Ovarian Cancer by Affecting the MicroRNA-374b-5p/HMGB3/Wnt-Î²-Catenin Pathway Axis. Frontiers in Oncology, 0, 12, .	2.8	1
415	RAD21 Confers Poor Prognosis and Affects Ovarian Cancer Sensitivity to Poly(ADP-Ribose)Polymerase Inhibitors Through DNA Damage Repair. Frontiers in Oncology, 0, 12, .	2.8	3
416	Association Between Metformin Use and the Risk, Prognosis of Gynecologic Cancer. Frontiers in Oncology, 0, 12, .	2.8	7
417	Exploring the Pharmacological Mechanism of the Effective Chinese Medicines Against Gynecological Cancer Based on Meta-Analysis Combined With Network Pharmacology Analysis. Frontiers in Oncology, 0, 12, .	2.8	3
418	The role of PIP5K1A in cancer development and progression. , 2022, 39, .		5
419	Protein expression profiling identifies a prognostic model for ovarian cancer. BMC Women's Health, 2022, 22, .	2.0	1
420	Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer. OncoImmunology, 2022, 11, .	4.6	16
421	Combined inhibition of BADSer99 phosphorylation and PARP ablates models of recurrent ovarian carcinoma. Communications Medicine, 2022, 2, .	4.2	5
422	Polarity switching of ovarian cancer cell clusters via <scp>SRC</scp> family kinase is involved in the peritoneal dissemination. Cancer Science, 2022, 113, 3437-3448.	3.9	3
423	High Expression of PARP1 in Tumor and Stroma Cells Predicts Different Prognosis and Platinum Resistance in Patients With Advanced Epithelial Ovarian Cancer. Frontiers in Oncology, 0, 12, .	2.8	1
424	FAP^{high} Î±â€SMA^{low} cancerâ€associated fibroblastâ€derived SLPI protein encapsulated in extracellular vesicles promotes ovarian cancer development via activation of PI3K/AKT and downstream signaling pathways. Molecular Carcinogenesis, 2022, 61, 910-923.	2.7	15
425	A Chinese classical prescription Guizhi-Fuling Wan in treatment of ovarian cancer: An overview. Biomedicine and Pharmacotherapy, 2022, 153, 113401.	5.6	4
426	Comprehensive Genomic Profiling in the Management of Ovarian Cancerâ€"National Results from Croatia. Journal of Personalized Medicine, 2022, 12, 1176.	2.5	0
427	Circular RNA circPBX3 promotes cisplatin resistance of ovarian cancer cells via interacting with IGF2BP2 to stabilize ATP7A mRNA expression. Human Cell, 2022, 35, 1560-1576.	2.7	9
428	Identification of Malignant Cell Populations Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer Using Single-Cell RNA Sequencing. Cancers, 2022, 14, 3580.	3.7	5

#	Article	IF	Citations
429	Retro-inversion follicle-stimulating hormone peptide-modified nanoparticles for delivery of PDK2 shRNA against chemoresistant ovarian cancer by switching glycolysis to oxidative phosphorylation. Cancer Nanotechnology, 2022, 13, .	3.7	2
430	Clinical outcomes of immunohistochemistry of the p53 Staining pattern in high-grade serous ovarian carcinoma. Obstetrics and Gynecology Science, 0, , .	1.6	1
431	BTN3A3 inhibits the proliferation, migration and invasion of ovarian cancer cells by regulating ERK1/2 phosphorylation. Frontiers in Oncology, 0, 12, .	2.8	4
432	Identification of the immune subtype of ovarian cancer patients by integrated analyses of transcriptome and single-cell sequencing data. Scientific Reports, 2022, 12, .	3.3	3
433	Downregulation of LEMD1-AS1 and Its Influences on the Diagnosis, Prognosis, and Immune Infiltrates of Epithelial Ovarian Cancer. Disease Markers, 2022, 2022, 1-8.	1.3	0
434	Machine-learning-based contrast-enhanced computed tomography radiomic analysis for categorization of ovarian tumors. Frontiers in Oncology, 0, 12, .	2.8	5
435	Purvalanol A induces apoptosis and reverses cisplatin resistance in ovarian cancer. Anti-Cancer Drugs, 0, Publish Ahead of Print, .	1.4	2
436	Decreased Levels of GSH Are Associated with Platinum Resistance in High-Grade Serous Ovarian Cancer. Antioxidants, 2022, 11, 1544.	5.1	9
437	Odd-skipped related 1 plays a tumor suppressor role in ovarian cancer via promoting follistatin-like protein 1 transcription. Human Cell, 2022, 35, 1824-1837.	2.7	2
438	BI 2536 induces gasdermin E-dependent pyroptosis in ovarian cancer. Frontiers in Oncology, 0, 12, .	2.8	10
439	Suppressing the PI3K/AKT Pathway by miR-30d-5p Mimic Sensitizes Ovarian Cancer Cells to Cell Death Induced by High-Dose Estrogen. Biomedicines, 2022, 10, 2060.	3.2	4
440	RAD54B mutations enhance the sensitivity of ovarian cancer cells to poly(ADP-ribose) polymerase (PARP) inhibitors. Journal of Biological Chemistry, 2022, 298, 102354.	3.4	1
441	Highly specific selenium nanosystems for fluorescent image-guided rapid diagnosis and pathological grading of ovarian malignant tumors. Chinese Chemical Letters, 2023, 34, 107764.	9.0	1
442	Association between XRCC3 rs861539 Polymorphism and the Risk of Ovarian Cancer: Meta-Analysis and Trial Sequential Analysis. BioMed Research International, 2022, 2022, 1-13.	1.9	1
443	Energy Substrate Transporters in High-Grade Ovarian Cancer: Gene Expression and Clinical Implications. International Journal of Molecular Sciences, 2022, 23, 8968.	4.1	9
444	Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancers. Nature Communications, 2022, 13, .	12.8	18
445	The disruption of the CCDC6 â€" PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	8.6	4
446	Japanese nationwide observational multicenter study of tumor *BRCA1*/*2* variant testing in advanced ovarian cancer. Cancer Science, 2023, 114, 271-280.	3.9	6

#	ARTICLE	IF	CITATIONS
447	Comprehensive analysis of prognosis-related alternative splicing events in ovarian cancer. RNA Biology, 2022, 19, 1007-1018.	3.1	4
448	Integrated analysis of the M2 macrophage-related signature associated with prognosis in ovarian cancer. Frontiers in Oncology, 0, 12, .	2.8	2
449	The SIRT1-HMGB1 axis: Therapeutic potential to ameliorate inflammatory responses and tumor occurrence. Frontiers in Cell and Developmental Biology, 0, 10, .	3.7	9
451	Plasma cfDNA methylation markers for the detection and prognosis of ovarian cancer. EBioMedicine, 2022, 83, 104222.	6.1	17
452	TRAF4 promotes the malignant progression of high-grade serous ovarian cancer by activating YAP pathway. Biochemical and Biophysical Research Communications, 2022, 627, 68-75.	2.1	3
453	Next-generation sequencing identifies potential novel therapeutic targets in Chinese HGSOC patients. Pathology Research and Practice, 2022, 238, 154074.	2.3	4
454	Naringenin suppresses epithelial ovarian cancer by inhibiting proliferation and modulating gut microbiota. Phytomedicine, 2022, 106, 154401.	5.3	9
455	Other rare ovarian cancers: Transitional cell carcinoma, malignant Brenner tumor, endometrioid carcinoma, mesothelioma, squamous cell carcinoma, sarcoma. , 2023, , 121-141.		0
456	Inositol monophosphatase 2 promotes epithelial ovarian cancer cell proliferation and migration by regulating the AKT/mTOR signaling pathway. Experimental and Therapeutic Medicine, 2022, 24, .	1.8	1
457	Discovery of semisynthetic celastrol derivatives exhibiting potent anti-ovarian cancer stem cell activity and STAT3 inhibition. Chemico-Biological Interactions, 2022, 366, 110172.	4.0	2
458	Targeting CD44-positive ovarian cancers via engineered paclitaxel prodrug nanoparticles for enhanced chemotherapeutic efficacy. Biomedicine and Pharmacotherapy, 2022, 154, 113655.	5.6	3
459	Artificial intelligence performance in image-based ovarian cancer identification: A systematic review and meta-analysis. EClinicalMedicine, 2022, 53, 101662.	7.1	28
460	Simultaneous detection of two ovarian cancer biomarkers in human serums with biotin-enriched dendritic mesoporous silica nanoparticles-labeled multiplex lateral flow immunoassay. Sensors and Actuators B: Chemical, 2022, 371, 132597.	7.8	11
461	PUMA overexpression dissociates thioredoxin from ASK1 to activate the JNK/BCL-2/BCL-XL pathway augmenting apoptosis in ovarian cancer. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2022, 1868, 166553.	3.8	5
462	The role of Platinum(IV)-based antitumor drugs and the anticancer immune response in medicinal inorganic chemistry. A systematic review from 2017 to 2022. European Journal of Medicinal Chemistry, 2022, 243, 114680.	5.5	20
463	Recent advances of non-coding RNAs in ovarian cancer prognosis and therapeutics. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211180.	3.2	7
464	Pre-diagnosis fiberâ€‰:â€‰carbohydrate intake ratio and mortality of ovarian cancer: results from a prospective cohort study. Food and Function, 2022, 13, 10046-10054.	4.6	3
465	La protein regulates protein expression by binding with the mRNAs of target genes and participates the pathological process of ovarian cancer. Frontiers in Oncology, 0, 12, .	2.8	0

#	ARTICLE	IF	CITATIONS
466	Detection of circulating tumor cells and evaluation of epithelial-mesenchymal transition patterns of circulating tumor cells in ovarian cancer. Translational Cancer Research, 2022, 11, 2636-2646.	1.0	3
468	Circular RNA-regulated autophagy is involved in cancer progression. Frontiers in Cell and Developmental Biology, 0, 10, .	3.7	4
469	Emerging roles of TRIM27 in cancer and other human diseases. Frontiers in Cell and Developmental Biology, 0, 10, .	3.7	2
470	Dominant-negative transforming growth factor-β receptor-armoured mesothelin-targeted chimeric antigen receptor T cells slow tumour growth in a mouse model of ovarian cancer. Cancer Immunology, Immunotherapy, 2023, 72, 917-928.	4.2	5
471	Comparing Intraperitoneal and Intravenous Personalized ErbB2CAR-T for the Treatment of Epithelial Ovarian Cancer. Biomedicines, 2022, 10, 2216.	3.2	2
472	Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer. Cell Death and Disease, 2022, 13, .	6.3	17
473	Prognostic and Predictive Role of Tumor-Infiltrating Lymphocytes (TILs) in Ovarian Cancer. Cancers, 2022, 14, 4344.	3.7	13
474	The PDGF Family Is Associated with Activated Tumor Stroma and Poor Prognosis in Ovarian Cancer. Disease Markers, 2022, 2022, 1-19.	1.3	6
475	Elaiophylin triggers paraptosis and preferentially kills ovarian cancer drug-resistant cells by inducing MAPK hyperactivation. Signal Transduction and Targeted Therapy, 2022, 7, .	17.1	26
477	Clinical significance of SPOCK2 expression signature for high-grade serous ovarian cancer patients. Frontiers in Genetics, 0, 13, .	2.3	0
478	Multi-omics Uncovering Different Faces of Clear Cell Ovarian Cancer. Clinical Cancer Research, 0, , OF1-OF2.	7.0	1
479	Management of advanced ovarian cancer in Leicester: The benefits of a paradigm shift in surgical approach. Journal of Obstetrics and Gynaecology Research, 2022, 48, 3233-3241.	1.3	0
480	TWIST1 induces proteasomal degradation of β-catenin during the differentiation of ovarian cancer stem-like cells. Scientific Reports, 2022, 12, .	3.3	1
481	Assessment of galectins -1, -3, -4, -8, and -9 expression in ovarian carcinoma patients with clinical implications. World Journal of Surgical Oncology, 2022, 20, .	1.9	4
482	High-Density Gold Nanoparticles Implanted on Mg/Fe LDH Nanoflowers Assisted Lateral Flow Immuno-Dipstick Assay for Visual Detection of Human Epididymal Protein 4. Biosensors, 2022, 12, 797.	4.7	1
483	Exploring nurses' experiences of caring for patients participating in cancer clinical trials. British Journal of Nursing, 2022, 31, S18-S24.	0.7	0
484	Longitudinal analysis of ovarian cancer death patterns during a rapid transition period (2005-2020) in Shanghai, China: A population-based study. Frontiers in Oncology, 0, 12, .	2.8	2
485	RSPO2 promotes progression of ovarian cancer through dual receptor-mediated FAK/Src signaling activation. IScience, 2022, 25, 105184.	4.1	2

#	ARTICLE	IF	CITATIONS
486	The BUMPy road of peritoneal metastases in ovarian cancer. Diagnostic and Interventional Imaging, 2022, 103, 448-459.	3.2	5
487	Synthesis of quercetin functionalized wurtzite type zinc oxide nanoparticles and their potential to regulate intrinsic apoptosis signaling pathway in human metastatic ovarian cancer. Life Sciences, 2022, 309, 121022.	4.3	17
488	The application of circulating tumor cell and cell-free DNA liquid biopsies in ovarian cancer. Molecular and Cellular Probes, 2022, 66, 101871.	2.1	5
489	Cáncer de ovario de células transicionales. , 2022, 26, .		0
491	Frailty and long-term survival of patients with ovarian cancer: A systematic review and meta-analysis. Frontiers in Oncology, 0, 12, .	2.8	2
492	Anti-Ovarian Cancer Conotoxins Identified from Conus Venom. Molecules, 2022, 27, 6609.	3.8	2
493	Identification of a novel ferroptosis-related gene signature associated with prognosis, the immune landscape, and biomarkers for immunotherapy in ovarian cancer. Frontiers in Pharmacology, 0, 13, .	3.5	1
495	Mfn2-mediated mitochondrial fusion promotes autophagy and suppresses ovarian cancer progression by reducing ROS through AMPK/mTOR/ERK signaling. Cellular and Molecular Life Sciences, 2022, 79, .	5.4	22
496	Frontline Management of Advanced Epithelial Ovarian Cancer: A Comprehensive Statement by an Expert Group from Middle East and North Africa Region. Current Women's Health Reviews, 2022, 19, .	0.2	0
497	An Acid Response IR780-Based Targeted Nanoparticle for Intraoperative Near-Infrared Fluorescence Imaging of Ovarian Cancer. International Journal of Nanomedicine, 0, Volume 17, 4961-4974.	6.7	6
498	Hsa_circ_0001445 works as a cancer suppressor via miR—576—5p/SFRP1 axis regulation in ovarian cancer. Cancer Medicine, 2023, 12, 5736-5750.	2.8	4
499	A Novel Antibody-Drug Conjugate Targeting Nectin-2 Suppresses Ovarian Cancer Progression in Mouse Xenograft Models. International Journal of Molecular Sciences, 2022, 23, 12358.	4.1	6
500	Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy. Frontiers in Immunology, 0, 13, .	4.8	2
501	Decitabine-Mediated Upregulation of CSPG4 in Ovarian Carcinoma Cells Enables Targeting by CSPG4-Specific CAR-T Cells. Cancers, 2022, 14, 5033.	3.7	6
502	Molecular subtypes based on cuproptosis-related genes and tumor microenvironment infiltration characterization in ovarian cancer. Cancer Cell International, 2022, 22, .	4.1	3
503	Novel Platinum Nanoclusters Activate PI3K/AKT/mTOR Signaling Pathway-Mediated Autophagy for Cisplatin-Resistant Ovarian Cancer Therapy. ACS Applied Materials & Interfaces, 2022, 14, 48502-48514.	8.0	9
504	Superior Anticancer Potential of Nano-Paclitaxel Combined Bevacizumab Treatment in Ovarian Cancer. Current Pharmaceutical Biotechnology, 2023, 24, 1204-1212.	1.6	1
505	Deubiquitylase PSMD14 inhibits autophagy to promote ovarian cancer progression via stabilization of LRPPRC. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2023, 1869, 166594.	3.8	8

#	Article	IF	Citations
506	Identification and prioritization of tumor associated antigens for immunotherapeutic and diagnostic capacity in epithelial ovarian cancer: A systematic literature review. Carcinogenesis, 0, , .	2.8	1
507	Deficiency of tumor-expressed B7-H3 augments anti-tumor efficacy of anti-PD-L1 monotherapy rather than the combined chemoimmunotherapy in ovarian cancer. Pharmacological Research, 2022, 186, 106512.	7.1	4
508	Meta-analyses reveal serum or plasma Interleukin-6 as a biomarker for malignant ovarian neoplasia. Cytokine, 2023, 161, 156073.	3.2	1
509	Relationship between different forms of dietary choline and ovarian cancer survival: findings from the ovarian cancer follow-up study, a prospective cohort study. Food and Function, 2022, 13, 12342-12352.	4.6	2
510	Targeting NaPi2b in ovarian cancer. Cancer Treatment Reviews, 2023, 112, 102489.	7.7	14
512	Integration of local and systemic immunity in ovarian cancer: Implications for immunotherapy. Frontiers in Immunology, 0, 13, .	4.8	8
513	TARDBP promotes ovarian cancer progression by altering vascular endothelial growth factor splicing. Oncogene, 2023, 42, 49-61.	5.9	2
514	Mitochondrial AAA protease gene associated with immune infiltration is a prognostic biomarker in human ovarian cancer. Pathology Research and Practice, 2022, 240, 154215.	2.3	3
515	Akt-Activated Endothelium Increases Cancer Cell Proliferation and Resistance to Treatment in Ovarian Cancer Cell Organoids. International Journal of Molecular Sciences, 2022, 23, 14173.	4.1	3
516	The Potential of MicroRNAs as Clinical Biomarkers to Aid Ovarian Cancer Diagnosis and Treatment. Genes, 2022, 13, 2054.	2.4	6
517	Molecular Management of High-Grade Serous Ovarian Carcinoma. International Journal of Molecular Sciences, 2022, 23, 13777.	4.1	6
518	Mechanism of exosomes in the tumor microenvironment in the abscopal effect (Review). International Journal of Oncology, 2022, 62, .	3.3	1
519	Polyetherimide‐and folic acid‐modified Fe_3O_4 nanospheres for enhanced magnetic hyperthermia performance. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2023, 111, 795-804.	3.4	4
520	Association between pre-diagnostic dietary copper, zinc, and copper-to-zinc ratio and severity of ovarian cancer. Frontiers in Nutrition, 0, 9, .	3.7	1
521	The pharmacological mechanism of Chinese herbs effective in treating advanced ovarian cancer: Integrated meta-analysis and network pharmacology analysis. Frontiers in Pharmacology, 0, 13, .	3.5	2
522	Circulating T-cell receptor diversity as predictive biomarker for PARP inhibitors maintenance therapy in high grade serous ovarian cancer. Gynecologic Oncology, 2023, 168, 135-143.	1.4	0
523	CRISPR/Cas9 as a molecular tool that extends beyond gene editing for ovarian cancer management. Critical Reviews in Oncogenesis, 2022, , .	0.4	0
524	The Dual Blockade of the TIGIT and PD-1/PD-L1 Pathway as a New Hope for Ovarian Cancer Patients. Cancers, 2022, 14, 5757.	3.7	10

#	ARTICLE	IF	CITATIONS
525	Comparative glycoproteomics study on the surface of SKOV3 versus IOSE80 cell lines. Frontiers in Chemistry, 0, 10, .	3.6	0
526	The first Chinese National Union of Real‐world Gynaecological Oncology Research and Patient Management Platform: AÂretrospective study. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, 129, 60-69.	2.3	1
527	Causal Effects of Circulating Lipid Traits on Epithelial Ovarian Cancer: A Two-Sample Mendelian Randomization Study. Metabolites, 2022, 12, 1175.	2.9	1
528	Higher thymocyte selection-associated high mobility group box (TOX) expression predicts poor prognosis in patients with ovarian cancer. BMC Cancer, 2022, 22, .	2.6	1
529	High co‐expression of <scp>SLC7A11</scp> and <scp>GPX4</scp> as a predictor of platinum resistance and poor prognosis in patients with epithelial ovarian cancer. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, 129, 40-49.	2.3	11
530	Does the primary treatment sequence affect post‐relapse survival in recurrent epithelial ovarian cancer? A real‐world multicentre retrospective study. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, 129, 70-78.	2.3	1
531	Neoadjuvant Chemotherapy in Ovarian Cancer: Are There Racial Disparities in Use and Survival?. Cancer Epidemiology Biomarkers and Prevention, 2023, 32, 175-182.	2.5	4
532	A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib. Scientific Reports, 2022, 12, .	3.3	14
533	An assessment of mismatch repair deficiency in ovarian tumours at a public hospital in Johannesburg, South Africa. South African Journal of Obstetrics and Gynaecology, 0, , 46-51.	0.1	0
534	Diagnostic Performances of Ultrasound-Based Models for Predicting Malignancy in Patients with Adnexal Masses. Healthcare (Switzerland), 2023, 11, 8.	2.0	3
535	tRNA-derived small RNA 3â€²U-tRFValCAC promotes tumour migration and early progression in ovarian cancer. European Journal of Cancer, 2023, 180, 134-145.	2.8	4
537	Machine learning-assisted ensemble analysis for the prediction of urinary tract infection in elderly patients with ovarian cancer after cytoreductive surgery. World Journal of Clinical Oncology, 0, 13, 967-979.	2.3	0
538	Hypoxia regulates tumour characteristic <scp>RNA</scp> modifications in ovarian cancers. FEBS Journal, 2023, 290, 2085-2096.	4.7	2
539	A 62-Year-Old Woman With a Large Abdominal Mass. JAMA - Journal of the American Medical Association, 0, , .	7.4	0
540	Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study Purposes. Cancers, 2022, 14, 6010.	3.7	4
541	The emerging roles of TLR and cGAS signaling in tumorigenesis and progression of ovarian cancer. Frontiers in Pharmacology, 0, 13, .	3.5	2
543	A single-center randomized controlled study of intraperitoneal hyperthermic chemoperfusion in combination of recombinant human tumor necrosis factor (TNF) in treatment of malignant ascites caused by advanced abdominal cancers. Medicine (United States), 2022, 101, e31883.	1.0	0
544	Tumor-secreted exosomal miR-141 activates tumor-stroma interactions and controls premetastatic niche formation in ovarian cancer metastasis. Molecular Cancer, 2023, 22, .	19.2	17

#	Article	IF	Citations
545	Construction and validation of a novel ferroptosis-related signature for evaluating prognosis and immune microenvironment in ovarian cancer. Frontiers in Genetics, 0, 13, .	2.3	6
546	Effect of CX3CL1/CX3CR1 gene polymorphisms on the clinical efficacy of carboplatin therapy in Han patients with ovarian cancer. Frontiers in Genetics, 0, 13, .	2.3	0
547	Ploidy Status of Ovarian Cancer Cell Lines and Their Association with Gene Expression Profiles. Biomolecules, 2023, 13, 92.	4.0	2
548	Preoperative serum microRNAs as potential prognostic biomarkers in ovarian clear cell carcinoma. Journal of Gynecologic Oncology, 2023, 34, .	2.2	4
549	A novel defined risk signature of endoplasmic reticulum stress-related genes for predicting the prognosis and immune infiltration status of ovarian cancer. Journal of Zhejiang University: Science B, 2023, 24, 64-77.	2.8	5
550	Analyzing the Expression of Ovarian Cancer Genes in PA-1 Cells Lines After the Treatment of Thymoquinone. Indian Journal of Gynecologic Oncology, 2023, 21, .	0.3	0
551	Niclosamide (NA) overcomes cisplatin resistance in human ovarian cancer. Genes and Diseases, 2023, 10, 1687-1701.	3.4	4
552	LRRC superfamily expression in stromal cells predicts the clinical prognosis and platinum resistance of ovarian cancer. BMC Medical Genomics, 2023, 16, .	1.5	2
553	Multiparameter single-cell proteomic technologies give new insights into the biology of ovarian tumors. Seminars in Immunopathology, 0, , .	6.1	2
554	The overexpressed regucalcin represses the growth via regulating diverse pathways linked to EGF signaling in human ovarian cancer SK-OV-3 cells: Involvement of extracellular regucalcin. Life Sciences, 2023, 314, 121328.	4.3	1
555	Honeycomb-like Structured Film, a Novel Therapeutic Device, Suppresses Tumor Growth in an In Vivo Ovarian Cancer Model. Cancers, 2023, 15, 237.	3.7	0
556	Proteomics of High-Grade Serous Ovarian Cancer Models Identifies Cancer-Associated Fibroblast Markers Associated with Clinical Outcomes. Biomolecules, 2023, 13, 75.	4.0	0
557	Long non-coding RNA SLC25A21-AS1 inhibits the development of epithelial ovarian cancer by specifically inducing PTBP3 degradation. Biomarker Research, 2023, 11, .	6.8	2
558	Nanocurcumin preserves kidney function and haematology parameters in DMBA-induced ovarian cancer treated with cisplatin via its antioxidative and anti-inflammatory effect in rats. Pharmaceutical Biology, 2023, 61, 298-305.	2.9	1
559	Combining TNFR2-Expressing Tregs and IL-6 as Superior Diagnostic Biomarkers for High-Grade Serous Ovarian Cancer Masses. Cancers, 2023, 15, 667.	3.7	4
560	New Perspectives on Reverse Translation: Brief History and Updates. Universitas Scientiarum, 2023, 28, 1-20.	0.4	0
561	Exploration of chemotherapy-free regimen after multi-line chemotherapy-induced renal impairment in recurrent ovarian cancer: Case report and literature review. Frontiers in Oncology, 0, 12, .	2.8	1
562	The Role of Selected Adipocytokines in Ovarian Cancer and Endometrial Cancer. Cells, 2023, 12, 1118.	4.1	8

#	ARTICLE	IF	CITATIONS
563	The correlation between women's various gynaecological diseases to ovarian cancer in Sulaimaniyah City, Iraq. Journal of International Medical Research, 2023, 51, 030006052311589.	1.0	1
564	CBL0137 activates ROS/BAX signaling to promote caspase-3/GSDME-dependent pyroptosis in ovarian cancer cells. Biomedicine and Pharmacotherapy, 2023, 161, 114529.	5.6	4
565	Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine. Gynecologic Oncology Reports, 2023, 47, 101155.	0.6	10
566	Role of SIRT5 in cancer. Friend or Foe?. Biochimie, 2023, 209, 131-141.	2.6	2
567	High FAM111B expression predicts aggressive clinicopathologic features and poor prognosis in ovarian cancer. Translational Oncology, 2023, 32, 101659.	3.7	1
568	Targeting PARP for the optimal immunotherapy efficiency in gynecologic malignancies. Biomedicine and Pharmacotherapy, 2023, 162, 114712.	5.6	5
573	Systematic Review and Meta-Analysis of O-RADS Ultrasound and O-RADS MRI for Risk Assessment of Ovarian and Adnexal Lesions. American Journal of Roentgenology, 2023, 221, 21-33.	2.2	10
574	PGD2 displays distinct effects in diffuse large B-cell lymphoma depending on different concentrations. Cell Death Discovery, 2023, 9, .	4.7	1
575	Computational Pathology for Breast Cancer and Gynecologic Cancer. Cancers, 2023, 15, 942.	3.7	0
577	Construction of Ovarian Cancer Prognostic Model Based on the Investigation of Ferroptosis-Related lncRNA. Biomolecules, 2023, 13, 306.	4.0	5
578	Synergistic effect of <scp>PARP</scp> inhibitor and <scp>BRD4</scp> inhibitor in multiple models of ovarian cancer. Journal of Cellular and Molecular Medicine, 2023, 27, 634-649.	3.6	3
579	Deep learning-based segmentation of epithelial ovarian cancer on T2-weighted magnetic resonance images. Quantitative Imaging in Medicine and Surgery, 2023, 13, 1464-1477.	2.0	5
581	Pt(II)-PLGA Hybrid in a pH-Responsive Nanoparticle System Targeting Ovarian Cancer. Pharmaceutics, 2023, 15, 607.	4.5	3
582	Investigating the suitability of in vitro cell lines as models for the major subtypes of epithelial ovarian cancer. Frontiers in Cell and Developmental Biology, 0, 11, .	3.7	5
583	Update on Prognostic and Predictive Markers in Mucinous Ovarian Cancer. Cancers, 2023, 15, 1172.	3.7	2
584	Neoadjuvant chemotherapy in advanced epithelial ovarian cancer by histology: A SEER based survival analysis. Medicine (United States), 2023, 102, e32774.	1.0	3
585	<scp>TPX2</scp> promotes ovarian tumorigenesis by interacting with Lamin A/C and affecting its stability. Cancer Medicine, 0, , .	2.8	1
586	Luteolin directly binds to KDM4C and attenuates ovarian cancer stemness via epigenetic suppression of PPP2CA/YAP axis. Biomedicine and Pharmacotherapy, 2023, 160, 114350.	5.6	5

#	ARTICLE	IF	CITATIONS
587	Expression level of CD117 (KIT) on ovarian cancer extracellular vesicles correlates with tumor aggressiveness. Frontiers in Cell and Developmental Biology, 0, 11, .	3.7	2
588	TIPE2 acts as a tumor suppressor and correlates with tumor microenvironment immunity in epithelial ovarian cancer. Aging, 0, , .	3.1	0
589	RNA epigenetic modifications in ovarian cancer: The changes, chances, and challenges. Wiley Interdisciplinary Reviews RNA, 2023, 14, .	6.4	2
590	The role of microRNA-613 and its related genes in ovarian cancer. Ukrainian Biochemical Journal, 2023, 94, 11-17.	0.5	0
591	Molecular mechanism of Wilms' tumor (Wt1) (+/â‰KTS) variants promoting proliferation and migration of ovarian epithelial cells by bioinformatics analysis. Journal of Ovarian Research, 2023, 16, .	3.0	1
592	The Use of Artificial Intelligence for Complete Cytoreduction Prediction in Epithelial Ovarian Cancer: A Narrative Review. Cancer Control, 2023, 30, 107327482311595.	1.8	0
593	Genetic predisposition to female infertility in relation to epithelial ovarian and endometrial cancers. Postgraduate Medical Journal, 2023, 99, 63-68.	1.8	1
594	Proteomic analysis reveals CAAP1 negatively correlates with platinum resistance in ovarian cancer. Journal of Proteomics, 2023, 277, 104864.	2.4	0
595	A NOTCH1 Mutation Found in a Newly Established Ovarian Cancer Cell Line (FDOVL) Promotes Lymph Node Metastasis in Ovarian Cancer. International Journal of Molecular Sciences, 2023, 24, 5091.	4.1	0
596	<i>ARID1A</i>mutations in cancer development: mechanism and therapy. Carcinogenesis, 2023, 44, 197-208.	2.8	6
597	Prognostic value of Î²-Arrestins in combination with glucocorticoid receptor in epithelial ovarian cancer. Frontiers in Oncology, 0, 13, .	2.8	0
598	Ovarian Cancerâ€"Insights into Platinum Resistance and Overcoming It. Medicina (Lithuania), 2023, 59, 544.	2.0	5
599	Primary Treatment Effects for High-Grade Serous Ovarian Carcinoma Evaluated by Changes in Serum Metabolites and Lipoproteins. Metabolites, 2023, 13, 417.	2.9	1
600	Tumor immune microenvironment changes are associated with response to neoadjuvant chemotherapy and long-term survival benefits in advanced epithelial ovarian cancer: A pilot study. Frontiers in Immunology, 0, 14, .	4.8	5
601	Potential Role of Vaginal Microbiota in Ovarian Cancer Carcinogenesis, Progression and Treatment. Pharmaceutics, 2023, 15, 948.	4.5	2
602	Nanotechnology-integrated ovarian cancer metastasis therapy: Insights from the metastatic mechanisms into administration routes and therapy strategies. International Journal of Pharmaceutics, 2023, 636, 122827.	5.2	3
603	MYH10 Combines with MYH9 to Recruit USP45 by Deubiquitinating Snail and Promotes Serous Ovarian Cancer Carcinogenesis, Progression, and Cisplatin Resistance. Advanced Science, 2023, 10, .	11.2	4
604	Circular RNA hsa_circ_0007444 inhibits ovarian cancer progression through miR-23a-3p/DICER1 axis. Acta Biochimica Et Biophysica Sinica, 2023, 55, 574-586.	2.0	3

#	Article	IF	Citations
605	Development of Nomogram Models Based on Peripheral Blood Score and Clinicopathological Parameters to Predict Preoperative Advanced Stage and Prognosis for Epithelial Ovarian Cancer Patients. Journal of Inflammation Research, 0, Volume 16, 1227-1241.	3.5	2
606	Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer. Frontiers in Pharmacology, 0, 14, .	3.5	4
607	Bufalin-loaded vitamin E succinate-grafted chitosan oligosaccharide/RGD-conjugated TPGS mixed micelles inhibit intraperitoneal metastasis of ovarian cancer. Cancer Nanotechnology, 2023, 14, .	3.7	1
608	The association of macronutrient quality and its interactions with energy intake with survival among patients with ovarian cancer: results from a prospective cohort study. American Journal of Clinical Nutrition, 2023, 117, 1362-1371.	4.7	2
609	Hsa_circ_0001535 inhibits the proliferation and migration of ovarian cancer by sponging miR-593-3p, upregulating PTEN expression. Clinical and Translational Oncology, 0, , .	2.4	0
610	New trends in diagnosing and treating ovarian cancer using nanotechnology. Frontiers in Bioengineering and Biotechnology, 0, 11, .	4.1	4
611	Impact of obesity on chemotherapy dosing of carboplatin and survival of women with ovarian cancer. British Journal of Cancer, 0, , .	6.4	0
612	FOXN3 inhibits the progression of ovarian cancer through negatively regulating the expression of RPS15A. Human Cell, 2023, 36, 1120-1134.	2.7	0
613	Advances in Pharmacological Effects of Lycorine Hydrochloride. World Journal of Cancer Research, 2023, 13, 23-29.	0.1	0
614	Recent advances in targeted therapy for pancreatic adenocarcinoma. World Journal of Gastrointestinal Oncology, 0, 15, 571-595.	2.0	10
615	Necroptosis-Related Modification Patterns Depict the Tumor Microenvironment, Redox Stress Landscape, and Prognosis of Ovarian Cancer. Oxidative Medicine and Cellular Longevity, 2023, 2023, 1-26.	4.0	0
616	Systematic analysis and prediction for disease burden of ovarian cancer attributable to hyperglycemia: a comparative study between China and the world from 1990 to 2019. Frontiers in Medicine, 0, 10, .	2.6	3
617	Novel insights into the multifaceted roles of m6A-modified LncRNAs in cancers: biological functions and therapeutic applications. Biomarker Research, 2023, 11, .	6.8	3
618	Cuâ€Catalyzed Asymmetric Kinetic Boron Conjugate Addition of Î³â€Substituted Î±,Î²â€Unsaturated Î³â€Lactams. Angewandte Chemie, 0, , .	2.0	0
619	Cuâ€Catalyzed Asymmetric Kinetic Boron Conjugate Addition of Î³â€Substituted Î±,Î²â€Unsaturated Î³â€Lactams. Angewandte Chemie - International Edition, 2023, 62, .	13.8	2
620	Analysis of risk factors for negative emotions in perioperative period of ovarian cancer patients and their impact on prognosis. Gland Surgery, 2023, .	1.1	0
621	Immune-Related Genesâ€™ Prognostic, Therapeutic and Diagnostic Value in Ovarian Cancer Immune-Related Gene Biomarker in Ovarian Cancer. Cancer Control, 2023, 30, 107327482311687.	1.8	1
622	Establishment of highly metastatic ovarian cancer model with omental tropism via inÂvivo selection. IScience, 2023, 26, 106719.	4.1	4

#	Article	IF	Citations
623	Temporal Trends of Ovarian Cancer Between 1990 and 2019, in Asian Countries by Geographical Region and SDI, Comparison with Global Data. Indian Journal of Gynecologic Oncology, 2023, 21, .	0.3	4
624	Identification of upregulated exosomal miRNAs between A2780 and A2780/DDP human ovarian cancer cells by high-throughput sequencing. Journal of Ovarian Research, 2023, 16, .	3.0	0
625	Consensus on the management of platinum-sensitive high-grade serous epithelial ovarian cancer in Lebanon. Gynecologic Oncology Reports, 2023, 47, 101186.	0.6	1
626	The myo-inositol biosynthesis rate-limiting enzyme ISYNA1 suppresses the stemness of ovarian cancer via Notch1 pathway. Cellular Signalling, 2023, 107, 110688.	3.6	3
627	Tripterygium glycosides reverse chemotherapy resistance in ovarian cancer by targeting the NRF2/GPX4 signal axis to induce ferroptosis of drug-resistant human epithelial ovarian cancer cells. Biochemical and Biophysical Research Communications, 2023, 665, 178-186.	2.1	2
628	Enhancement of sonodynamic treatment of ovarian cancer based on Pt-B-P ternary nanoparticles. Nanomedicine: Nanotechnology, Biology, and Medicine, 2023, 51, 102686.	3.3	0
629	A novel autophagy-related gene signature associated with prognosis and immune microenvironment in ovarian cancer. Journal of Ovarian Research, 2023, 16, .	3.0	2
630	Computable structured aptamer for targeted treatment of ovarian cancer. Frontiers in Genetics, 0, 14, .	2.3	1
631	SPON1 is an independent prognostic biomarker for ovarian cancer. Journal of Ovarian Research, 2023, 16, .	3.0	1
632	Thymoquinone enhanced the antitumor activity of cisplatin in human bladder cancer 5637 cells in vitro. Molecular Biology Reports, 2023, 50, 5767-5775.	2.3	1
633	The joint role of methylation and immune-related lncRNAs in ovarian cancer: Defining molecular subtypes and developing prognostic signature. Translational Oncology, 2023, 34, 101704.	3.7	1
634	Leucyl and Cystinyl Aminopeptidase as a Prognostic-Related Biomarker in OV Correlating with Immune Infiltrates. Pharmacogenomics and Personalized Medicine, 0, Volume 16, 551-568.	0.7	0
635	Differential molecular pathway expression according to chemotherapeutic response in ovarian clear cell carcinoma. BMC Women's Health, 2023, 23, .	2.0	2
636	Prognostic significance of systemic immune-inflammation index in patients with ovarian cancer: a meta-analysis. Frontiers in Oncology, 0, 13, .	2.8	1
637	Tumor metabolism rewiring in epithelial ovarian cancer. Journal of Ovarian Research, 2023, 16, .	3.0	1
638	Characterization of candidate factors associated with the metastasis and progression of high-grade serous ovarian cancer. Chinese Medical Journal, 2023, 136, 2974-2982.	2.3	4
639	Emerging peptide therapeutics for the treatment of ovarian cancer. Expert Opinion on Emerging Drugs, 2023, 28, 129-144.	2.4	1
640	Emerging roles of circ_NRIP1 in tumor development and cancer therapy (Review). Oncology Letters, 2023, 26, .	1.8	1

#	Article	IF	Citations
641	Stability Characterization of the Novel Anti-Cancer HM-10/10 HDL-Mimetic Peptide. International Journal of Molecular Sciences, 2023, 24, 10054.	4.1	0
642	MOB kinase activator 1A acts as an oncogene by targeting PI3K/AKT/mTOR in ovarian cancer. Discover Oncology, 2023, 14, .	2.1	0
643	Potential applications of DNA methylation testing technology in female tumors and screening methods. Biochimica Et Biophysica Acta: Reviews on Cancer, 2023, 1878, 188941.	7.4	0
644	Recent advances in targeted therapy for ovarian cancer. , 2022, 8, 28-35.		0
646	Predicting Neoadjuvant Chemotherapy Response and High-Grade Serous Ovarian Cancer From CT Images in Ovarian Cancer with Multitask Deep Learning: A Multicenter Study. Academic Radiology, 2023, 30, S192-S201.	2.5	1
647	Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors. International Journal of Molecular Sciences, 2023, 24, 10859.	4.1	5
648	Associating Peritoneal Metastasis With <scp>T2â€Weighted MRI</scp> Images in Epithelial Ovarian Cancer Using Deep Learning and Radiomics: A Multicenter Study. Journal of Magnetic Resonance Imaging, 0, , .	3.4	2
649	Peptides for diagnosis and treatment of ovarian cancer. Frontiers in Oncology, 0, 13, .	2.8	2
650	SORL1 stabilizes ABCB1 to promote cisplatin resistance in ovarian cancer. Functional and Integrative Genomics, 2023, 23, .	3.5	4
651	Advances of exosomal miRNAs in the diagnosis and treatment of ovarian cancer. Discover Oncology, 2023, 14, .	2.1	1
652	Identification and validation of m5c-related lncRNA risk model for ovarian cancer. Journal of Ovarian Research, 2023, 16, .	3.0	1
653	Molecular and phenotypic characteristics influencing the degree of cytoreduction in highâ€grade serous ovarian carcinomas. Cancer Medicine, 2023, 12, 14183-14195.	2.8	0
654	Postâ€translational modifications of histones: Mechanisms, biological functions, and therapeutic targets. MedComm, 2023, 4, .	7.2	12
655	Anemarrhenasaponin I suppresses ovarian cancer progression via inhibition of SHH signaling pathway. Oncologie, 2023, 25, 233-243.	0.7	0
656	Autophagyâ€related gene <i>PXN</i> as a prognostic marker: Promotion of ovarian cancer progression by suppressing the p110Î²/Vps34/Beclin1 pathway. Cell Biochemistry and Function, 2023, 41, 599-608.	2.9	1
657	Profiling the metabolome of uterine fluid for early detection of ovarian cancer. Cell Reports Medicine, 2023, 4, 101061.	6.5	1
658	Nanocarriers for photodynamic-gene therapy. Photodiagnosis and Photodynamic Therapy, 2023, 43, 103644.	2.6	2
659	MiR-590-5p promotes cisplatin resistance via targeting hMSH2 in ovarian cancer. Molecular Biology Reports, 2023, 50, 6819-6827.	2.3	1

#	Article	IF	Citations
660	An analysis of clinical characteristics and prognosis of endometrioid ovarian cancer based on the SEER database and two centers in China. BMC Cancer, 2023, 23, .	2.6	1
661	Human leukocyte antigenâ€G in gynaecological tumours. International Journal of Immunogenetics, 2023, 50, 163-176.	1.8	2
662	Dual Energy, Spectral and Photon Counting CT for Evaluation of the Gastrointestinal Tract. Radiologic Clinics of North America, 2023, , .	1.8	0
664	Identification of <scp>N1</scp> methyladenosineâ€related biomarker predicting overall survival outcomes and experimental verification in ovarian cancer. Journal of Obstetrics and Gynaecology Research, 0, , .	1.3	0
665	Research Progress of Natural Product Myricetin against Ovarian Cancer. Advances in Clinical Medicine, 2023, 13, 10996-11001.	0.0	0
667	AhRR and PPP1R3C: Potential Prognostic Biomarkers for Serous Ovarian Cancer. International Journal of Molecular Sciences, 2023, 24, 11455.	4.1	0
668	An explainable machine learning ensemble model to predict the risk of ovarian cancer in BRCA-mutated patients undergoing risk-reducing salpingo-oophorectomy. Frontiers in Oncology, 0, 13, .	2.8	0
670	A Comprehensive Overview of Various Cancer Types and Their Progression. , 2023, , 1-17.		1
672	Anisomycin inhibits the activity of human ovarian cancer stem cells via regulating antisense RNA NCBP2â€AS2/MEK/ERK/STAT3 signaling. Journal of Gene Medicine, 2024, 26, .	2.8	1
673	Single-cell analyses implicate ascites in remodeling the ecosystems of primary and metastatic tumors in ovarian cancer. Nature Cancer, 2023, 4, 1138-1156.	13.2	9
674	CircSLC39A8 attenuates paclitaxel resistance in ovarian cancer by regulating the miRâ€185â€5p/BMF axis. Translational Oncology, 2023, 36, 101746.	3.7	1
675	The performance of Carbohydrate Antigen 125-Thomsen-nouveau and anti-MÃ¼llerian hormone combined with CA125, Human epididymis protein 4 and Risk of Malignancy Algorithm in diagnosis for patients with Epithelial ovarian cancer. Clinical Biochemistry, 2023, 119, 110615.	1.9	0
676	Urological procedures performed by gynecologists: Activity profile in a gynecological surgery department, 10-year observation cohort. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2023, 288, 204-210.	1.1	0
677	CT-based radiomics nomogram analysis for assessing BRCA mutation status in patients with high-grade serous ovarian cancer. Acta Radiologica, 0, , .	1.1	0
678	Interferon-Î¼ is a tumour suppressor and restricts ovarian cancer. Nature, 2023, 620, 1063-1070.	27.8	9
680	A single-cell landscape of pre- and post-menopausal high-grade serous ovarian cancer ascites. IScience, 2023, 26, 107712.	4.1	0
681	Deep Learning Radiomics Nomogram Based on Magnetic Resonance Imaging for Differentiating Type I/II Epithelial Ovarian Cancer. Academic Radiology, 2023, , .	2.5	1
682	OSR1 downregulation indicates an unfavorable prognosis and activates the NF-κB pathway in ovarian cancer. Discover Oncology, 2023, 14, .	2.1	0

#	Article	IF	Citations
683	MUC16 stimulates neutrophils to an inflammatory and immunosuppressive phenotype in ovarian cancer. Journal of Ovarian Research, 2023, 16, .	3.0	2
684	Comprehensive analyses of fatty acid metabolism-related lncRNA for ovarian cancer patients. Scientific Reports, 2023, 13, .	3.3	0
685	RBM15â€'mediating MDR1 mRNA m6A methylation regulated by the TGFâ€Î² signaling pathway in paclitaxelâ€'resistant ovarian cancer. International Journal of Oncology, 2023, 63, .	3.3	1
686	Mass spectrometry-based proteomics as an emerging tool in clinical laboratories. Clinical Proteomics, 2023, 20, .	2.1	8
687	Prediction of benign and malignant ovarian tumors using Resnet34 on ultrasound images. Journal of Obstetrics and Gynaecology Research, 2023, 49, 2910-2917.	1.3	1
688	A methylation- and immune-related lncRNA signature to predict ovarian cancer outcome and uncover mechanisms of chemoresistance. Journal of Ovarian Research, 2023, 16, .	3.0	5
689	Deep Learning Can Predict Bevacizumab Therapeutic Effect and Microsatellite Instability Directly from Histology in Epithelial Ovarian Cancer. Laboratory Investigation, 2023, 103, 100247.	3.7	0
690	<scp>IGF2BP2</scp> promotes ovarian cancer growth and metastasis by upregulating <scp>CKAP2L</scp> protein expression in an <scp>m⁶A</scp>â€dependent manner. FASEB Journal, 2023, 37, .	0.5	2
691	The DDUP protein encoded by the DNA damage-induced CTBP1-DT lncRNA confers cisplatin resistance in ovarian cancer. Cell Death and Disease, 2023, 14, .	6.3	0
692	Heterogeneity and treatment landscape of ovarian carcinoma. Nature Reviews Clinical Oncology, 2023, 20, 820-842.	27.6	3
693	Diagnostics and treatment of ovarian cancer in the era of precision medicine - opportunities and challenges. Frontiers in Oncology, 0, 13, .	2.8	3
694	Selinexor in Combination with Decitabine Attenuates Ovarian Cancer in Mice. Cancers, 2023, 15, 4541.	3.7	1
695	Targeting PUF60 prevents tumor progression by retarding mRNA decay of oxidative phosphorylation in ovarian cancer. Cellular Oncology (Dordrecht), 2024, 47, 157-174.	4.4	1
696	Metabolic reprogramming of three major nutrients in platinum-resistant ovarian cancer. Frontiers in Oncology, 0, 13, .	2.8	0
697	RAD51D Secondary Mutation-Mediated Resistance to PARP-Inhibitor-Based Therapy in HGSOC. International Journal of Molecular Sciences, 2023, 24, 14476.	4.1	1
698	Hormone Receptors and Epithelial Ovarian Cancer: Recent Advances in Biology and Treatment Options. Biomedicines, 2023, 11, 2157.	3.2	0
700	Pharmacological inhibition of KDM1A/LSD1 enhances estrogen receptor beta-mediated tumor suppression in ovarian cancer. Cancer Letters, 2023, 575, 216383.	7.2	0
701	Cancer-Associated Fibroblast Mimetic AIE Probe for Precision Imaging-Guided Full-Cycle Management of Ovarian Cancer Surgery. Analytical Chemistry, 2023, 95, 15068-15077.	6.5	1

#	ARTICLE	IF	CITATIONS
702	MRE11:p.K464R mutation mediates olaparib resistance by enhancing DNA damage repair in HGSOC. Cell and Bioscience, 2023, 13, .	4.8	0
703	Replication stress and defective checkpoints make fallopian tube epithelial cells putative drivers of high-grade serous ovarian cancer. Cell Reports, 2023, 42, 113144.	6.4	1
704	A Novel pyroptosis-related signature for predicting prognosis and evaluating tumor immune microenvironment in ovarian cancer. Journal of Ovarian Research, 2023, 16, .	3.0	0
705	Function of m^{5}C RNA methyltransferase NOP2 in high-grade serous ovarian cancer. Cancer Biology and Therapy, 2023, 24, .	3.4	2
706	Clinical significance of L1CAM expression in metastatic tubo-ovarian high-grade serous carcinoma. Gynecologic Oncology, 2023, 176, 76-81.	1.4	0
707	C1632 inhibits ovarian cancer cell growth and migration by inhibiting LIN28ÂB/let-7/FAK signaling pathway and FAK phosphorylation. European Journal of Pharmacology, 2023, 956, 175935.	3.5	1
710	Long noncoding RNA KCNMB2-AS1 acts as an oncogene in ovarian cancer. Acta Biochimica Et Biophysica Sinica, 2023, 55, 1844-1846.	2.0	0
711	The PAPSS1 gene is a modulator of response to cisplatin by regulating estrogen receptor alpha signaling activity in ovarian cancer cells. Journal of Ovarian Research, 2023, 16, .	3.0	0
712	Phellopterin attenuates ovarian cancer proliferation and chemoresistance by inhibiting the PU.1/CLEC5A/PI3K-AKT feedback loop. Toxicology and Applied Pharmacology, 2023, 477, 116691.	2.8	1
713	Achieving enhanced sensitivity and accuracy in carcinoembryonic antigen (CEA) detection as an indicator of cancer monitoring using thionine/chitosan/graphene oxide nanocomposite-modified electrochemical immunosensor. Environmental Research, 2023, 238, 117163.	7.5	1
714	Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design. IScience, 2023, 26, 107952.	4.1	1
715	Copine 1 predicts poor clinical outcomes by promoting M2 macrophage activation in ovarian cancer. Carcinogenesis, 2023, 44, 748-759.	2.8	1
716	Low dose PFDA induces DNA damage and DNA repair inhibition by promoting nuclear cGAS accumulation in ovarian epithelial cells. Ecotoxicology and Environmental Safety, 2023, 265, 115503.	6.0	2
717	Biotin decorated celastrol-loaded ZIF-8 nano-drug delivery system targeted epithelial ovarian cancer therapy. Biomedicine and Pharmacotherapy, 2023, 167, 115573.	5.6	1
718	Purification of Circulating Tumor Cells Based on Multiantibody-Modified Magnetic Nanoparticles and Molecular Analysis toward Epithelial Ovarian Cancer Detection. ACS Sensors, 0, , .	7.8	0
719	Artificial intelligence-based risk stratification, accurate diagnosis and treatment prediction in gynecologic oncology. Seminars in Cancer Biology, 2023, 96, 82-99.	9.6	3
721	Clinical significance and immune infiltration analyses of a novel coagulation-related signature in ovarian cancer. Cancer Cell International, 2023, 23, .	4.1	0
722	Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma. Journal of Experimental and Clinical Cancer Research, 2023, 42, .	8.6	2

#	Article	IF	Citations
723	The roles of FXYD family members in ovarian cancer: an integrated analysis by mining TCGA and GEO databases and functional validations. Journal of Cancer Research and Clinical Oncology, 0, , .	2.5	0
724	The Roles of Histone Deacetylases in the Regulation of Ovarian Cancer Metastasis. International Journal of Molecular Sciences, 2023, 24, 15066.	4.1	0
725	Triptolide inhibits epithelial ovarian tumor growth by blocking the hedgehog/Gli pathway. Aging, 0, , .	3.1	0
726	The Prognosis Predictive Score around Neo Adjuvant Chemotherapy (PPSN) Improves Diagnostic Efficacy in Predicting the Prognosis of Epithelial Ovarian Cancer Patients. Cancers, 2023, 15, 5062.	3.7	1
727	Vascular normalization: reshaping the tumor microenvironment and augmenting antitumor immunity for ovarian cancer. Frontiers in Immunology, 0, 14, .	4.8	3
728	Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges. Cancers, 2023, 15, 5300.	3.7	1
730	Klotho in Cancer: Potential Diagnostic and Prognostic Applications. Diagnostics, 2023, 13, 3357.	2.6	0
731	Regucalcin Is a Potential Regulator in Human Cancer: Aiming to Expand into Cancer Therapy. Cancers, 2023, 15, 5489.	3.7	2
732	Deciphering tumor immune microenvironment differences between high-grade serous and endometrioid ovarian cancer to investigate their potential in indicating immunotherapy response. Journal of Ovarian Research, 2023, 16, .	3.0	0
733	Synergy of the microRNA Ratio as a Promising Diagnosis Biomarker for Mucinous Borderline and Malignant Ovarian Tumors. International Journal of Molecular Sciences, 2023, 24, 16016.	4.1	0
734	Unveiling the novel immune and molecular signatures of ovarian cancer: insights and innovations from single-cell sequencing. Frontiers in Immunology, 0, 14, .	4.8	0
735	Liquid biopsy in ovarian cancer in China and the world: current status and future perspectives. Frontiers in Oncology, 0, 13, .	2.8	0
736	Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1/2 and RAD51. Nature Communications, 2023, 14, .	12.8	0
737	Simultaneous detection of CA-125 and mesothelin by gold nanoparticles in surface plasmon resonance. Sensing and Bio-Sensing Research, 2024, 43, 100609.	4.2	0
738	Nano- and Micromedicines as Intraperitoneal Therapy in Ovarian Cancer: Critical Overview and Focus on Pharmaceutical Manufacturing Under cGMP. , 2023, , 79-105.		0
739	The recent advancements of ferroptosis in the diagnosis, treatment and prognosis of ovarian cancer. Frontiers in Genetics, 0, 14, .	2.3	0
740	A Review of PARP-1 Inhibitors: Assessing Emerging Prospects and Tailoring Therapeutic Strategies. Drug Research, 2023, 73, 491-505.	1.7	0
741	Mendelian randomization analysis to elucidate the causal relationship between small molecule metabolites and ovarian cancer risk. Frontiers in Oncology, 0, 13, .	2.8	0

#	ARTICLE	IF	CITATIONS
743	A systemic analysis of monocarboxylate transporters in ovarian cancer and possible therapeutic interventions. Channels, 2023, 17, .	2.8	0
744	Tertiary lymphoid structures in gynecological cancers: prognostic role, methods for evaluating, antitumor immunity, and induction for therapy. Frontiers in Oncology, 0, 13, .	2.8	0
745	The microbiome and ovarian cancer: insights, implications, and therapeutic opportunities. Journal of Cancer Metastasis and Treatment, 0, , .	0.8	0
746	Machine learning–derived identification of prognostic signature for improving prognosis and drug response in patients with ovarian cancer. Journal of Cellular and Molecular Medicine, 0, , .	3.6	0
747	Recent Advances in Surface Plasmon Resonance (SPR) Technology for Detecting Ovarian Cancer Biomarkers. Cancers, 2023, 15, 5607.	3.7	0
748	Revealing the inhibitory effect of VASH1 on ovarian cancer from multiple perspectives. Cancer Biology and Therapy, 2023, 24, .	3.4	1
749	Proteomic characterization of epithelial ovarian cancer delineates molecular signatures and therapeutic targets in distinct histological subtypes. Nature Communications, 2023, 14, .	12.8	0
750	Identifying Explainable Machine Learning Models and a Novel SFRP2+ Fibroblast Signature as Predictors for Precision Medicine in Ovarian Cancer. International Journal of Molecular Sciences, 2023, 24, 16942.	4.1	0
751	The causal relationship between ankylosing spondylitis and the risk of ovarian cancer. Human Immunology, 2023, , 110738.	2.4	0
752	Ferroptosis in epithelial ovarian cancer: a burgeoning target with extraordinary therapeutic potential. Cell Death Discovery, 2023, 9, .	4.7	0
753	Engineering extracellular vesicles mimetics for targeted chemotherapy of drug-resistant ovary cancer. Nanomedicine, 0, , .	3.3	0
754	A follicle-stimulating hormone receptor-targeted near-infrared fluorescent probe for tumor-selective imaging and photothermal therapy. Materials Today Bio, 2024, 24, 100904.	5.5	1
755	Multifactor assessment of ovarian cancer reveals immunologically interpretable molecular subtypes with distinct prognoses. Frontiers in Immunology, 0, 14, .	4.8	0
757	USP43 impairs cisplatin sensitivity in epithelial ovarian cancer through HDAC2-dependent regulation of Wnt/β-catenin signaling pathway. Apoptosis: an International Journal on Programmed Cell Death, 0, , .	4.9	0
758	Artificial intelligence and allied subsets in early detection and preclusion of gynecological cancers. Biochimica Et Biophysica Acta: Reviews on Cancer, 2023, 1878, 189026.	7.4	1
759	Imaging of Peritoneal Carcinomatosis in Advanced Ovarian Cancer: CT, MRI, Radiomic Features and Resectability Criteria. Cancers, 2023, 15, 5827.	3.7	0
760	Targeted inhibition of the ATR/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2MUT ovarian cancer cells. Scientific Reports, 2023, 13, .	3.3	0
761	Endometriosis and epithelial ovarian cancer: a two-sample Mendelian randomization analysis. Scientific Reports, 2023, 13, .	3.3	0

#	ARTICLE	IF	CITATIONS
763	Novel proteomic technologies to address gaps in pre-clinical ovarian cancer biomarker discovery efforts. Expert Review of Proteomics, 2023, 20, 439-450.	3.0	0
765	Mitogen-Activated Protein Kinase 15 Is a New Predictive Biomarker and Potential Therapeutic Target for Ovarian Cancer. International Journal of Molecular Sciences, 2024, 25, 109.	4.1	0
766	Cellular zinc metabolism and zinc signaling: from biological functions to diseases and therapeutic targets. Signal Transduction and Targeted Therapy, 2024, 9, .	17.1	0
767	Nanoparticle-Encapsulated Epirubicin Efficacy in the Inhibition of Growth of Orthotopic Ovarian Patient-Derived Xenograft in Immunocompromised Mice. International Journal of Molecular Sciences, 2024, 25, 645.	4.1	0
768	Next-generation sequencing-based analysis of homologous recombination repair gene variant in ovarian cancer. Heliyon, 2024, 10, e23684.	3.2	0
769	Construction and validation of molecular subtype and signature of immune cellâ€related telomeric genes and prediction of prognosis and immunotherapy efficacy in ovarian cancer patients. Journal of Gene Medicine, 2024, 26, .	2.8	0
770	Combined use of Anlotinib with chemotherapy in patients with advanced ovarian cancer: a real-world cohort study and meta-analysis. Therapeutic Advances in Medical Oncology, 2024, 16, .	3.2	0
771	MAPRE3 as an epigenetic target of EZH2 restricts ovarian cancer proliferation in vitro and in vivo. Experimental Cell Research, 2024, 435, 113913.	2.6	0
773	Human Fallopian Tube-Derived Organoids with TP53 and RAD51D Mutations Recapitulate an Early Stage High-Grade Serous Ovarian Cancer Phenotype In Vitro. International Journal of Molecular Sciences, 2024, 25, 886.	4.1	1
774	S100A4/NF-ÎºB axis mediates the anticancer effect of epigallocatechin-3-gallate in platinum-resistant ovarian cancer. IScience, 2024, 27, 108885.	4.1	0
775	PARP inhibitors in ovarian cancer. Seminars in Oncology, 2024, 51, 45-57.	2.2	0
776	HMGB1 enhances the migratory and invasive abilities of A2780/DDP cells by facilitating epithelial to mesenchymal transition via GSKâ€3Î². Experimental and Therapeutic Medicine, 2024, 27, .	1.8	0
778	Tumor-derived small extracellular vesicles facilitate omental metastasis of ovarian cancer by triggering activation of mesenchymal stem cells. Cell Communication and Signaling, 2024, 22, .	6.5	0
779	Anoikis related genes may be novel markers associated with prognosis for ovarian cancer. Scientific Reports, 2024, 14, .	3.3	0
780	Roles, underlying mechanisms and clinical significances of LINC01503 in human cancers. Pathology Research and Practice, 2024, 254, 155125.	2.3	0
781	Myricetin, a natural inhibitor of CD147, increases sensitivity of cisplatin in ovarian cancer. Expert Opinion on Therapeutic Targets, 2024, 28, 83-95.	3.4	0
782	CX3CR1 is a potential biomarker of immune microenvironment and prognosis in epithelial ovarian cancer. Medicine (United States), 2024, 103, e36891.	1.0	0
786	Predictive Value of Machine Learning for Platinum Chemotherapy Responses in Ovarian Cancer: Systematic Review and Meta-Analysis. Journal of Medical Internet Research, 0, 26, e48527.	4.3	0

#	ARTICLE	IF	CITATIONS
787	Hematological and Neurological Expressed 1 Promotes Tumor Progression Through mTOR Signaling in Ovarian Cancer. Reproductive Sciences, 0, , .	2.5	0
788	Combined radiomics-clinical model to predict platinum-sensitivity in advanced high-grade serous ovarian carcinoma using multimodal MRI. Frontiers in Oncology, 0, 14, .	2.8	0
789	Single-cell transcriptome analysis of epithelial, immune, and stromal signatures and interactions in human ovarian cancer. Communications Biology, 2024, 7, .	4.4	1
790	Characterization of hypoxia-responsive states in ovarian cancer to identify hot tumors and aid adjuvant therapy. Discover Oncology, 2024, 15, .	2.1	0
791	High-grade serous carcinoma of unknown primary origin associated with STIC clinically presented as isolated inguinal lymphadenopathy: a case report. Frontiers in Oncology, 0, 13, .	2.8	0
792	A novel clinical nomogram for predicting cancer-specific survival in patients with non-serous epithelial ovarian cancer: A real-world analysis based on the Surveillance, Epidemiology, and End Results database and external validation in a tertiary center. Translational Oncology, 2024, 42, 101898.	3.7	0
793	Anoikis-related signature predicts prognosis and characterizes immune landscape of ovarian cancer. Cancer Cell International, 2024, 24, .	4.1	0
794	Computational identification of DNA damage-relevant lncRNAs for predicting therapeutic efficacy and clinical outcomes in cancer. Computers in Biology and Medicine, 2024, 171, 108107.	7.0	0
795	A Pt(II) complex bearing N-heterocycle ring induced ferroptotic cell death in ovarian cancer. Journal of Inorganic Biochemistry, 2024, 253, 112502.	3.5	0
796	An exosome-derived lncRNA signature identified by machine learning associated with prognosis and biomarkers for immunotherapy in ovarian cancer. Frontiers in Immunology, 0, 15, .	4.8	0
797	Nutritional interventions during treatment for ovarian cancer: A narrative review and recommendations for future research. Maturitas, 2024, 183, 107938.	2.4	0
798	Statistically developed stable Camptothecin-loaded Soluplus/TPGS mixed micelles for improved ovarian cancer treatment. Journal of Dispersion Science and Technology, 0, , 1-14.	2.4	0
799	Comprehensive analysis of single cell and bulk data develops a promising prognostic signature for improving immunotherapy responses in ovarian cancer. PLoS ONE, 2024, 19, e0298125.	2.5	0
800	Fatty acid metabolism-related lncRNA prognostic signatureÂfor serous ovarian carcinoma. Epigenomics, 2024, 16, 309-329.	2.1	0
801	Î²-Sitosterol targets ASS1 for Nrf2 ubiquitin-dependent degradation, inducing ROS-mediated apoptosis via the PTEN/PI3K/AKT signaling pathway in ovarian cancer. Free Radical Biology and Medicine, 2024, 214, 137-157.	2.9	0
802	Tripartite-motif 3 represses ovarian cancer progression by downregulating lactate dehydrogenase A and inhibiting AKT signaling. Molecular and Cellular Biochemistry, 0, , .	3.1	0
803	ZSWIM4 inhibition improves chemosensitivity in epithelial ovarian cancer cells by suppressing intracellular glycine biosynthesis. Journal of Translational Medicine, 2024, 22, .	4.4	0
804	Laparoscopic versus laparotomic surgical treatment in apparent stage I ovarian cancer: a multi-center retrospective cohort study. World Journal of Surgical Oncology, 2024, 22, .	1.9	0

#	Article	IF	Citations
805	Development and validation of an ultrasoundâ€'based radiomics nomogram to predict lymph node status in patients with high-grade serous ovarian cancer: a retrospective analysis. Journal of Ovarian Research, 2024, 17, .	3.0	0
806	Different Patterns of Platinum Resistance in Ovarian Cancer Cells with Homologous Recombination Proficient and Deficient Background. International Journal of Molecular Sciences, 2024, 25, 3049.	4.1	0
807	EM-transcriptomic signature predicts drug response in advanced stages of high-grade serous ovarian carcinoma based on ascites-derived primary cultures. Frontiers in Pharmacology, 0, 15, .	3.5	0
808	Trends in survival of ovarian clear cell carcinoma patients from 2000 to 2015. Frontiers in Oncology, 0, 14, .	2.8	0
809	Current trends and emerging patterns in the application of nanomaterials for ovarian cancer research: a bibliometric analysis. Frontiers in Pharmacology, 0, 15, .	3.5	0
810	Endogenous Microbacteria Can Contribute to Ovarian Carcinogenesis by Reducing Iron Concentration in Cysts: A Pilot Study. Microorganisms, 2024, 12, 538.	3.6	0
811	Investigating the mechanisms of drug resistance and prognosis in ovarian cancer using single-cell RNA sequencing and bulk RNA sequencing. Aging, 0, , .	3.1	0
812	Ovarian cancer is detectable from peripheral blood using machine learning over T-cell receptor repertoires. Briefings in Bioinformatics, 2024, 25, .	6.5	0
813	The impact of varying levels of residual disease following cytoreductive surgery on survival outcomes in patients with ovarian cancer: a meta-analysis. BMC Women's Health, 2024, 24, .	2.0	0
814	How to optimize the immune checkpoint blockade therapy for cancers?. Oncologie, 2024, .	0.7	0
815	Systemic treatment of ovarian cancer. Onkologie (Czech Republic), 2024, 18, 25-31.	0.1	0
816	Realâ€world study of lymphadenectomy in patients with advanced epithelial ovarian cancer. Journal of Obstetrics and Gynaecology Research, 2024, 50, 663-670.	1.3	0
817	Identification of different subtypes of ovarian cancer and construction of prognostic models based on glutamine-metabolism associated genes. Heliyon, 2024, 10, e27358.	3.2	0
819	Emerging Advances in Endometrial Cancer: Integration of Molecular Classification into Staging for Enhanced Prognostic Accuracy and Implications for Racial Disparities. Cancers, 2024, 16, 1172.	3.7	0
820	A clinical prognostic model of oxidative stress-related genes linked to tumor immune cell infiltration and the prognosis of ovarian cancer patients. Heliyon, 2024, 10, e28442.	3.2	0
821	Peritumoral <scp>MRI</scp> Radiomics Features Increase the Evaluation Efficiency for Response to Chemotherapy in Patients With Epithelial Ovarian Cancer. Journal of Magnetic Resonance Imaging, 0, , .	3.4	0